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Abstract  
Lung cancer is the most common cause of cancer-associated mortality in males and 
females globally. Widespread research is currently focused on the development of 
novel approaches for targeting non small cell lung cancer with different therapeutic 
nanotechnologies. In this study, a sensitive and selective HPLC method was 
developed for the quantification of afatinib (AFT) in formulations.   Novel drug 
delivery systems based on cationic (CL) and pH-sensitive liposomes (PSL) for AFT 
were developed, with different ratios of lipid to AFT, using a film hydration method. 
The obtained liposomes had a small particle size of less than 50 nm with a low 
polydispersibilty index and acceptable zeta potential. The highest Encapsulation 
Efficiency (EE%) of AFT reached 43.20%, 50.20%, and 52.01% for NL (Non 
targeting liposomes), PSL, CL, respectively at the 1:0.5 ratio of AFT: lipids. The in 
vitro release study confirmed that all formulations had sustained release profiles in 
pH 7.4. However, in acidic pH values, PSL exhibited fast release. The stability study, 
conducted at 4°C and 25°C for 1 month, showed that the characteristics of liposomes 
in liquid form did not change significantly over this period. In vitro cytotoxicity 
studies revealed high antitumor activity of PSL on all cell lines at 0.75 µM 
concentration after 24 h exposure, based on using the Annexin V assay. A proteomics 
study identified 12 proteins which can be used as biomarkers capable of prediction of 
treatment response and choice of therapy for two different types of human NSCLC 
cells (H-1975 and H-1650). 
Spray drying was used to produce nanocomposite microparticles (NCMPs) using L-
leucine and coated using different ratios of chitosan for the optimized PSL NPs. The 
particles had a corrugated surface except at high CH ratios, where more homogenous 
and smooth particles with some small indentations were obtained. The powder 
properties showed good flow properties and reproducible size. Coated NCMPs 
showed a delayed drug release profile compared to PSL NPs and the best correlation 
with the Higuchi model. A stability study at 40°C/ 75% ± 5% relative humidity (RH) 
showed large changes in the drug content for all coated NCMPs powders. Analysis of 
the in vitro aerosolization performance demonstrated a mass median aerodynamic 
diameter (MMAD) of 3.24 – 5.85 µm and fine particle fraction (FPF%) of 54.20-
33.66%. The particle size of the reconstituted powders was ˂ 100 nm, which is within 
the size range to be effectively taken up by tumor cells. Assessment of the stability of 
spray dried liposomes after 3 months of storage at 40 °C/75% RH, showed that fusion 
xv 
 
and aggregation of the liposomes occurred in all samples tested. The C1NCMPs (lipid: 
LEU: CH ratio of 1:1.5:0.5) exhibited the highest FPF (51.2%) and fine particle dose 
(FPD) (40.0 µg of AFT) indicating deep lung deposition. Further cell viability studies 
of C1 NCMP, at a concentration of 0.75 μM on H-1975 NSCLC cell line showed a 
good toxicity profile comparable to PSL nanoparticles (NPs).  The obtained data 
indicates that pulmonary delivery of PSL NCMPs is a potential new clinical strategy 
for better targetability and delivery of AFT for the treatment of lung cancer. 
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General Introduction 
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1.1. Introduction 
1.1.1. Lung cancer 
Lung cancer is responsible for 1.38 million annual mortalities worldwide [1]. It is the 
most common cause of cancer associated mortality in males and the second in 
females after breast cancer [2]. In the Kingdom of Saudi Arabia, the rate of lung 
cancer has increased significantly in recent years, accounting for 3.7 % of all newly 
diagnosed cancers.  This is mainly due to the increased prevalence of cigarette 
smoking among Saudi men and women. Recently, the Saudi Cancer Registry has 
reported that lung cancer ranked the fifth most common in males and fifteenth in 
females [3]. Of the 3.7 % of those with lung cancer, 326 (74.9 %) were males and 
109 (25.1 %) females, with a male to female ratio of 3:1 [4, 5]. Alamoudi also 
reported that lung cancer was the most common cause of hospitalization in Saudi 
male patients admitted with respiratory diseases [5]. In the United Kingdom, lung 
cancer is among the most frequently diagnosed types of cancer and accounts for 20% 
of new cancer cases (34,000 new patients) annually [6].  
Lung cancer is commonly related to smoking and is thus often classified as a social 
disease with an associated stigma attached. The majority (85 %) of cases of lung 
cancer are due to long-term tobacco smoking. These cases are often caused by a 
combination of genetic factors and exposure to radon gas, asbestos, second-hand 
smoke, or other forms of air pollution. Contrary to popular belief, lung cancer also 
affects non-smokers and about 10–15% of cases occur in people who have never 
smoked [7]. For example, in women only 65% of cancer deaths are a result of 
smoking, with lung cancer killing more women than breast, ovarian and uterine 
cancers combined.  Regardless of cause, death from lung cancer is high; with less 
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than 10% of those diagnosed surviving for 5 years [8]. This may partly be due to the 
length of time between the onset of cancer symptoms and the patient’s presentation 
to health care, leading to more late-stage diagnosis and therefore, less eligibility for 
potentially curative treatment.  
The most common symptoms of lung cancer are dyspnea, cough (including coughing 
up blood), chest pain, and weight loss. Clinically, lung cancer is divided into two 
main types according to the characteristics of the disease and its response to therapy 
(Figure 1- 1).  
Trachea 
Lymph node 
Left lung Right 
Bronchioles 
Left main stem 
bronchus 
Small cell lung cancer Non small cell lung 
Mass 
of 
Figure 1- 1: The structure of the lung and histological photographs of non small 
cell lung cancer (left bottom) and small cell lung cancer (right Bottom) [9]. 
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Non small cell lung cancer (NSCLC) can be located in the mid-chest, but it is also 
found in other parts of the lung. According to the current World Health Organization 
classification [9],  NSCLC is classified into the following histological types:  
1. Squamous carcinoma, the most common type, found in the central or inner 
parts of the lung and/or along the trachea, accounting for 35% of all NSCLC. 
The cells are well differentiated and metastases occur comparatively late.  
2. Adenocarcinoma, accounts for approximately, 27% of lung cancers and is 
associated with brain and bones metastases. It is the most common type of 
lung cancer in people working with asbestos and is also common in non-
smokers, older people and women.  
3. Large-cell carcinoma, which accounts for 10% of all lung cancers. It is less 
well differentiated than the first type and metastasizes earlier.  
In the same classification, small cell lung carcinomas (SCLC) is typically more 
centrally located in lungs and includes the following histological types: typical 
carcinoid tumor, atypical carcinoid tumor and large cell neuroendocrine carcinoma.  
Accounting for about 85% of all lung cancer cases, NSCLC is the most common of 
the two types while the remaining 15 % are  small cell lung cancer [10]. Clinical 
staging and identification of the histological type are essential to finding the best 
therapeutic strategy for treating such patients. Therefore, the classification of lung 
cancer into SCLC and NSCLC was necessary for treatment of patients with lung 
cancer in hospital routine practice. However, for clinical treatment, NSCLC sub 
classification by molecular factors and immunohistochemistry has become 
mandatory. Explanations for this are; better understanding of cancer biology, favored 
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efficacy or toxicity of novel drugs in subtypes of NSCLC, and the demonstration of 
therapeutically related driver mutations in subcategories of NSCLC [11]. 
1.1.1. Management of NSCLC 
Surgery is the treatment of choice in the early stages of NSCLC.  Unfortunately, 
surgery is only accessible to a few patients because around 70% of patients with 
NSCLC will present with advanced tumors. Patients with more advanced stages of 
disease are treated with chemotherapy, radiation therapy, or chemoradiotherapy [12].  
Chemotherapy has a significant role in treating patients with both SCLC and NSCLC. 
For patients with early-stage NSCLC, chemotherapy can be used either before 
surgery is carried out or following surgery to help treat the patient and improve long-
term survival rates. However, conventional chemotherapy is highly non-specific in 
targeting the drugs to the cancer cells causing undesirable side-effects to healthy 
tissues  such as neurotoxicity [13] and bone marrow suppression [14, 15]. 
New technologies and understandings can now be used to discover targets for 
innovative drugs. Fortunately, over the past decade, there have been major advances 
in the understanding of the pathogenesis and management of lung cancers, leading to 
a remarkable evolution in diagnosis, improved staging and new therapeutic options. 
Therefore, many genes and proteins, including small-molecule signal transduction 
inhibitors implicated in tumour growth, are now potential clinical targets and are being 
developed for the treatment of cancer. The tyrosine kinases, an example of such 
targets, are enzymes that phosphorylate proteins leading to the activation of signal-
transduction pathways which play an important role in different biological processes, 
including cell growth, differentiation, and death. Therefore, the discovery of frequent 
molecular alterations in NSCLC, particularly epidermal growth factor receptor 
(EGFR) mutations, has led to a new treatment paradigm that includes targeted agents. 
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EGFR is a transmembrane glycoprotein which widely expressed (40-80%) in NSCLC.  
[16].  
One of the signaling pathways often dysregulated in malignant epithelial cells is the 
Erb family of receptor tyrosine kinases, also known as the HER family, and their 
associated ligands. They comprise four structurally related transmembrane receptor 
tyrosine kinases (Figure 1- 2); epidermal growth factor receptor (EGFR; ErbB1), 
human EGFR 2 (HER2; ErbB2), ErbB3 and ErbB4. The activation of these receptors 
leads to phosphorylation of tyrosine kinase in EGFR proteins, which in turn triggers 
multiple signal transduction cascades [17]. The resulting phosphotyrosine residues are 
significant components of multiple downstream signaling processes necessary to 
activate cell proliferation and other cell responses, including angiogenesis, cell 
migration, and decreased apoptosis, all of which can lead to tumor growth [18]. 
Knowing the role of the EGFR receptor signaling cascade in cancer led to the 
development of new agents designed to specifically target these receptors. Significant 
progression was made in the treatment of NSCLC following the observation that 
mutations in the kinase domain of EGFR strongly linked with sensitivity to EGFR 
tyrosine kinase inhibitors (TKIs)  [19]. 
Recently, numerous EGFR targeting agents have been approved for the treatment of 
NSCLC. Erlotinib and gefitinib, the first-generation small-molecule EGFR-TKIs, 
bind reversibly to the kinase domain and efficiently inhibit both wild-type and 
mutated EGFR. These drugs cause notable improvements in progression-free survival 
in comparison to conventional chemotherapy. However, primary and acquired 
resistance against first-generation EGFR-TKIs usually occurs within a year [20]. The 
problems with resistance to first-generation EGFR-TKIs supports the need for 
development of new strategies for such patients. These include agents which can form 
7 
 
irreversible covalent bonds to the EGFR TK domain (in contrary to first-generation 
TKIs that act through competitive binding with ATP to induce reversible inhibition), 
so theoretically extending inhibition of signaling. Also, many of the new drugs are 
designed to block other EGFR family members, leading to inhibition of similar 
signaling pathways which may be involved in resistance [21]. Afatinib (AFT) 
targeting of several members of the EGFR family, is one such strategy[22]. 
 
 
 
 
 
1.2. Afatinib  
Afatinib (AFT) is a novel, potent, irreversible small-molecule tyrosine kinase 
inhibitor (TKI). In July 2013, the U.S. Food and Drug Administration (FDA) 
approved AFT as an oral once-daily tablet (produced as the dimaleate salt, Gilotrif; 
Boehringer Ingelheim) for the first-line treatment of patients with metastatic NSCLC 
and EGFR mutation [23].  It is an aniline–quinazoline derivative (Figure 1- 3). Gilotrif 
Figure 1- 2: Signal transduction. Adapted with permission from [15]. 
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tablets are available in 40 mg, 30 mg, or 20 mg of AFT (equivalent to 59.12 mg, 44.34 
mg, or 29.56 mg AFT dimaleate) [24]. The suggested dose of AFT is 40 mg once 
daily; but a maximum of 50 mg/day or a minimum of 20 mg/day, can be prescribed 
based on tolerability [25]. At the approved AFT dose of 40 mg, there is low AFT–
drug interaction potential. Afatinib pharmacokinetics are not affected by commonly 
co-prescribed medicines such as cytochrome P450 inducers or inhibitors and acid-
reducing agents, but concomitant treatment with strong inducers or inhibitors of P-gp 
can affect the pharmacokinetics of AFT, and consequently caution is advisable with 
this combination. Treatment is continued until disease progression or undesirable 
toxicity occurs [26].  
 
 
 
 
 
 
 
 
Figure 1- 3: Chemical structure of afatinib 
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1.2.1. Mechanism of action 
Afatinib binds irreversibly to the intracellular kinase domains, inhibiting tyrosine 
kinase autophosphorylation, and subsequently preventing intracellular signaling.  By 
targeting the ErbB family of receptors (Figure 1- 2), AFT has broader antitumor 
activity against receptors with acquired mutations that are resistant to the first 
generation of TKIs [27]. The irreversible binding of AFT, unlike other compounds 
which are reversible, provides a sustained, selective, covalent and complete ErbB 
family blockade. This means that AFT may provide the benefit of enhanced inhibition 
of tumor cell proliferation and effectiveness across a wide range of cancers compared 
to first generation of EGFR TKIs, which offer single, reversible, receptor blocking 
[28].  
1.2.2. Pharmacokinetics 
After oral dosing, AFT reaches peak plasma concentrations within 2 to 5 h,  in patients 
with solid tumours (Table 1- 1) [29]. The absolute bioavailability of AFT in humans 
has not been studied but the relative bioavailability was 92% after a single dose of a 
20 mg tablet compared with an oral solution and was ≈ 95 % plasma protein bound 
in vitro [10]. Afatinib has a large volume of distribution, with a mean value of 2,870 
L reported at steady state in patients receiving AFT 40 mg once daily [29]. 
Furthermore, patient  age, weight, gender or ethnicity do not have a clinically related 
effect on the clearance or exposure of AFT [30]. A high fat meal has a moderate effect 
on AFT exposure and thus, AFT should be taken without food. There is inter-patient 
variability in AFT plasma concentrations in patients receiving the drug [31].                                                                                   
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Table 1- 1: Pharmacokinetic parameters of 40 mg Afatinib after multiple once-daily 
doses in cancer patients [29-30]. 
 
1.2.3. Safety and tolerability of afatinib 
Clinical studies indicate that AFT is well tolerated with most adverse effects stated as 
mild-to-moderate. The most common gastrointestinal problem is diarrhea, but nausea, 
vomiting, mucositis and fatigue were also detected, similar to those reported with 
other TKIs and were commonly self-limiting or effectively controlled by suitable 
medication. Regardless of the adverse events reported, only 8% of patients treated 
with AFT discontinued the treatment [32]. 
Afatinib demonstrated effective inhibition of wild-type EGFR, HER2, and ErbB4 at 
low nano-molar concentrations, while reversible TKIs erlotinib and geﬁtinib only 
Parameter 
 
Afatinib 
Usual starting dose (mg/day) 40 
Tmax (h) 2 – 5 
Vd (L) 2870 
Protein binding  95 
t1/2 (h) 37 
F absolute Not known 
CL (mL/min) 1070 – 1390 
Metabolism  Minimal hepatic metabolism 
Renal excretion ˂ 5% 
Accumulation  2 to 3-fold 
Food effect AUC     39% 
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inhibited EGFR [33]. In comparison with erlotinib and geﬁtinib, AFT was also active 
against NSCLC cells that overexpress HER2. Afatinib induced apoptosis and 
inhibited cellular growth in several tumor cell lines, and caused tumor shrinkage in 
xenograft models of many cancer types, including NSCLC, colorectal cancer, 
pancreatic cancer, and head and neck squamous cell cancer [34]. Afatinib also 
confirmed good activity in preclinical models of tumor cells resistant to reversible 
EGFR inhibitors, demonstrating that irreversible ErbB family blockade was effective 
in patients with reversible EGFR-TKI-resistant illness [34, 35].  
Also, AFT inhibited EGFR harboring L858R/T790M at low nano-molar 
concentrations (half maximal effective concentration (IC50), 9–10 nM. Moreover, 
AFT inhibited cell growth in cultured lung cancer cells (IC50, 99 nM) and a lung 
cancer xenograft model harboring L858R/T790M. In addition, AFT is active in vitro 
and in vivo in the presence of “secondary” mutations; a mechanism responsible for 
50%–60% of cases of resistance. A study of xenograft models showed that AFT has 
a broad spectrum of antitumor activity in vivo demonstrating an improvement in 
overall survival as a first line treatment as compared to conventional chemotherapy. 
In patients with lung squamous cell cancer, AFT established an important increase in 
overall survival and progression-free survival compared with erlotinib [36].  
Taken together, the potent activity and the irreversible inhibition of signaling from all 
ErbB family receptor dimers formed by EGFR, HER2, and ErbB4, and preclinical 
antitumor activity of AFT, provides biological validation of the effectiveness of AFT 
in clinical studies. Therefore, AFT is considered as a new treatment choice for lung 
cancer patients hence there is an urgent need to develop novel and innovative 
technologies to overcome the side effects and for better targeting to fight this fatal 
cancer.  
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1.3. Nano-scale drug delivery systems   
Nanotechnology includes the creation and use of materials, devices or systems at 
nanoscale (3-200 nm), that can be fabricated using a variety of materials [37].  
Advances in nanotechnology have contributed to recent innovations for cancer 
treatments, including diagnostic techniques, by enabling interactions with cells at a 
molecular level. Frequently, it costs less to develop new ways of administering 
existing drugs with improved efficacy and bioavailability, reduced dosing frequency 
and lower side effects, than to develop new drugs [38, 39].  
Multifunctional and smart nanomaterials are  multipurpose carriers for different 
biomedical applications such as tumor targeting [40], and drug delivery [41]. Cancer 
nanotechnology has the potential to offer new opportunities for personalized oncology 
in which therapy is based on each individual’s molecular and cellular profile [42].  
Nanoparticles (NPs) are emerging as a new class of therapeutics for cancer.  NPs are 
solid, colloidal particles containing macromolecular materials with a size range from 
10 nm to 100 nm. Nanoparticles can be designed to help therapeutic drugs easily cross 
biological barriers, enable molecular interactions, and to detect molecular changes. 
Generally, the drug is entrapped, dissolved, adsorbed, attached and/or encapsulated 
into or onto a nano-matrix [43]. Compared to microparticles, nanoparticles have a 
larger surface area with modifiable optical, electronic, magnetic, and biologic 
properties. Additionally, new methods of administration can be explored by including 
the existing drug in a new drug delivery system (DDS) [44].  
There is now extensive interest in formulating anticancer drugs for pulmonary 
delivery, inspired by the potential utility of the lung as a portal for the administration 
of drugs to treat both lung disease and for systemic delivery [45]. Using dry powder 
inhalation (DPI) for targeted pulmonary delivery is an attractive choice that can be 
13 
 
optimized for inhalation to create a flexible platform that can accommodate wide 
range of active pharmaceutical ingredients and medical conditions [46]. Even though 
some chemotherapeutics can be delivered directly through the pulmonary or 
intratracheal route [47], most anticancer drugs cannot be inhaled in their traditional 
form and need a specific DDS to enable deposition directly into the lungs [48]. 
Recently, several different DDS have been developed for the inhalation of different 
classes of drugs but not all have been effective because of their limited capability to 
specifically target tumor sites. For example, in cancer chemotherapy, many drugs kill 
normal cells as well as the cancer cells. Another difficulty includes premature drug 
loss through fast clearance from the blood stream and metabolism. Thus, there is a 
growing need for development of drug delivery strategy that selectively targets tumor 
cells and direct local delivery. Moreover, the development of new DDS is a 
continuous procedure, starting from the early research to product development, 
passing through all stages of clinical trials and finally resulting in commercial 
utilization [49].   
Nano-sized systems have received significant attention as pharmaceutical carriers 
with a varied range of applications, including vaccine adjuvants, carriers in medical 
diagnostics and analytical biochemistry, support matrices for chemical ingredients 
and solubilizing agents for various materials. Moreover,  attention has been given to 
their role as an interface between the patient and the drug, and can be administered 
through different routes (oral, intravenous, transdermal or inhalation)  [44]. The DDS 
can be successfully formulated and enhance the therapeutic efficacy of a great number 
of pulmonary anticancer drugs [49].  This holds considerable promise for improving 
the treatment of many diseases by minimizing nonspecific toxicity and enhancing the 
efficacy of therapy. Therefore, nanocarriers are considered as new, “smart” DDSs 
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which can be targeted towards specific sites and organs and triggered to release the 
drug whenever needed [50]. These DDS are created from materials that are sensitive 
to a wide range of external stimuli, including light, ultrasound, electrical and magnetic 
fields, and specific molecules [51].  The most studied DDS are nanocarriers which are 
mostly associated with drugs that are pharmacologically potent but could not be 
administered as a “free” drug owing to high toxicity or low bioavailability[52]. 
Nanocarrier systems are known to increase drug bioavailability and therapeutic 
efficiency and decrease nonspecific toxicity of potent anticancer drugs [53]. In 
addition, their biocompatibility, and ability to deliver the drug into the target tissue 
using low drug doses make nanocarriers an ideal delivery vehicle [54] . Therapeutic 
strategies to effectively target tumor sites can be classified into two different 
strategies: passive targeting and active targeting [55]. 
1.3.1. Passive targeting 
Passive targeting takes advantage of the enhanced permeation and retention (EPR) of 
tumor tissue. This EPR results in higher local permeability and retention of drug 
loaded particles and allows the possibility of targeting cancer cells in which the fast 
and newly growing cancerous tissue interrupts the structure of normal tissue and 
vessel walls, which in turn, can be easily accessible to toxic chemotherapeutic drugs. 
Some drugs can be administered as prodrugs or inactive drugs, which once exposed 
to the tumor environment, can be switched on to become highly active [56]. The 
passive cancer targeting potentially benefits from imperfect vasculature and poor 
lymphatic drainage produced by angiogenesis in tumor tissues. The accumulation of 
drug loaded particles in the tumor tissues could be enhanced by optimizing the 
properties and features of the particulate carriers, such as surface charge, chemistry, 
and particle size [57].  
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1.3.2. Active targeting 
A molecular targeting moiety can be used to precisely target biomarkers or receptors 
on the tumor cells, thus enabling better accumulation of the drug in the tumor tissue. 
Active cancer targeting has been extensively studied using DDS to target tumor cells 
and decrease the systemic toxicity [58]. This strategy can be used to direct 
nanoparticles to cell surface carbohydrates, receptors, and antigens. Active targeting 
can also use targeting ligands on the surface of nanoparticles towards  membrane 
receptors on cancer cells causing enhanced cellular uptake of nanoparticles[56].  
1.4. Inhalation therapy for lung cancer 
Administration of drugs to the lung by aerosolisation has been used for many years to 
treat mainly localized disease conditions within the bronchi. The pulmonary route of 
administration can distribute therapeutic agents to the tumor sites while minimizing 
their distribution in the systemic circulation. Systemic drug delivery is less successful 
because only a limited amount of the chemotherapeutic drugs arrives at the lung 
tumors, even when administered at high dose. A more promising therapeutic index 
can be attained for lung treatment when drugs are administered locally by inhalation 
rather than by other routes. 
Pulmonary delivery is  a  non-invasive route, with the advantages of; site-specific 
delivery, good permeability of the pulmonary epithelium, lower enzymatic activity 
compared to the gut, a large surface area, a very thin absorption membrane, and 
massive vascularization (5 L/min), which rapidly distributes molecules throughout the 
body [59]. Compared to other delivery routes the greatest advantages of pulmonary 
administration are the improved bioavailability of drugs in the lung due to higher 
absorption rates, decreased drug doses and a fast onset of action. Therefore, inhalation 
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therapy has been used to treat local lung diseases such as microbial infections and 
asthma along with systemic diseases like diabetes and it plays a significant role in 
gene delivery [60]. Also, inhalation therapy can help in the fight against cancer by 
delivering drugs locally to the tumor cell in lungs [61].  However, the delivery of 
anticancer agents by inhalation can be limited due to [49, 62]: 
1) The short residence of the inhaled drug in the lung and the potential for systemic 
adverse effects. 
2) The low aqueous solubility of drugs which may lead to local irritation and 
inflammation in the lung airways.  
3) The poor intracellular penetration of some drugs to treat intracellular pathogens. 
4) The inability of drugs to target tumor cells and tissues selectively.   
The development of novel approaches for targeting lung cancer with different 
therapeutic carriers is of great importance. Carriers providing sustained drug release 
in the lungs could improve therapeutic outcomes of inhaled medicines. Their 
objectives are to keep the drug load within the lungs for an extended period of time 
and to increasingly release the drug locally at therapeutic levels. Sustained therapeutic 
drug concentrations should improve local therapeutic efficacy and decrease systemic 
adverse effects as the bio distribution through the systemic circulation is minimized. 
In addition, a sustained-release inhaled formulation could avoid peaks in local drug 
concentrations that could be toxic to the pulmonary tissue. This is mainly relevant for 
chemotherapeutic drugs.  
1.5. Liposomes  
Liposomes are small spherical vesicles, formed with one or more lipid bilayers 
constituted of amphiphilic lipids and may include cholesterol. Usually, liposomes are 
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used to deliver hydrophobic or hydrophilic drugs through inclusion in either the lipid 
bilayer itself or encapsulation in the inner aqueous core, respectively (Figure 1- 4).  
Liposomes can take the form of a wide variety of structures, but all consist of one or 
more lipid bilayers enclosing an aqueous space [63]. Liposomes can be made using 
different lipids; neutral, anionic or cationic, from natural or synthetic sources, and 
most include cholesterol (CH) or surfactants. The most commonly used lipids are the 
lecithins: phosphatidylethanolamine (PE), phosphatidylcholine (PC), 
phosphatidylglycerol (PG), phosphatidylinositol, phosphatidylserine and 
sphingomyelin. Most of these lipids exist naturally in the lung therefore have good 
biocompatibility [64]. Liposome properties can be determined by lipid composition, 
surface charge, size, lamellarity and the technique of preparation. There are different 
techniques for liposomal preparation, which result in vesicles that may be small or 
large unilamellar vesicles, or multilamellar vesicles [65] .  
 
 
 
Aqueous core  
Lipid bilayer  
Figure 1- 4: (a) The structure of one POPC (1-palmitoyl-2-oleoyl-sn-glycero-3-
phosphocholine) lipid molecule, showing the hydrophilic head and hydrophobic tail. 
POPC is a naturally-occurring lipid and is commonly used in the production of 
synthetic liposomes. (b) The heads and tails of the lipid interact to self-assemble into 
a membrane structure, and (c) a lipid vesicle. Adapted with permission from The 
Royal Society of Chemistry [63]. Copyright 2013. 
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1.5.1. Classification of Liposomes 
Liposomes can be classified according to their size, formation method or the number 
of bilayers in the vesicle. Based on the number of bilayers, they are often split into 
small unilamellar vesicles (SUVs; 25-100 nm), large unilamellar vesicles (LUVs; 0.1-
1 µm), and multilamellar vesicles (MLVs; 0.1-20 µm) (Figure 1- 5) [65]. MLVs are 
usually made using a thin-film hydration method, the most common method. Other 
methods include, organic solvent injection  [66], reverse-phase evaporation [67], and 
dehydration-rehydration [68]. All the liposome preparation techniques involve 4 basic 
steps as illustrated in Figure 1- 6. Techniques such as sonication, membrane extrusion, 
homogenization and/or freeze-thawing are used to control the size and size 
distribution. Furthermore, oligolamellar vesicles (0.1-1 µm) have been reported; these 
are liposomes containing  two or three bilayers which can be produced using a reverse 
phase evaporation technique [67] or an ethanol-based proliposome technology [69]. 
For the pulmonary delivery of liposomes, MLVs are usually prepared by the 
traditional thin-film hydration technique, followed by either sonication to produce 
SUVs, or membrane extrusion to get smaller MLVs or LUVs [70].  
 
Figure 1- 5: A schematic representation of vesicle size and lamellarity classification 
system of liposomes. Small unilamellar vesicles are ˂100 nm in diameter and large 
unilamellar vesicles are between 100 and 1000 nm. Multilamellar vesicles have more 
than one membrane layer, and can encapsulate smaller vesicles. Adapted with 
permission from The Royal Society of Chemistry [63]. Copyright 2013. 
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1.5.2. Types of liposomal drug delivery systems 
Liposomal DDS have been reported to improve the administration of 
chemotherapeutic agents in the treatment of lung cancer and inhibition of metastases 
when compared to other routes of administration [71]. Liposome encapsulation can 
increase the antitumor efficacy of the incorporated drugs by providing more selective 
delivery or targeting to the tumor tissue, while in other cases, toxicity is decreased by 
avoidance of critical normal tissues [72]. 
Due to extensive developments in liposome technology, a number of FDA approved 
nano-formulations of drugs for different diseases, are available on the market for 
human use (Table 1- 2) or are under different phases of clinical trials. Treating cancer 
was the utmost widely explored area in terms of clinically approved products utilizing 
liposomes. The first nano-sized liposomal based product was Doxil® (1995) for the 
Figure 1- 6: Common Steps in liposomes preparation 
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treatment of patients with ovarian cancer and AIDS-related Kaposi’s sarcoma. Doxil® 
has a prolonged circulation time, better release and accumulation in the tumor site, 
which increased drug efficiency and decreased adverse effects. Later, DaunoXome® 
was developed for the delivery of daunorubicin, for the management of advanced 
HIV-associated Kaposi’s sarcoma [73].  
Liposomal formulations are also available for conventional chemotherapeutic drugs 
such as platinum derivatives [74]. In patients with NSCLC, clinical trials have shown 
reduced toxicities following administration of liposome formulations of cisplatin, but 
without significant improvements in efficacy relative to free drug [75].  
Lipoplatin (Regulon, Inc.) is one of the most promising liposomal platinum drug 
formulations under clinical trial. Pre-clinical studies of Lipoplatin in animals reported 
that it has lower side effects, and remarkably lower nephrotoxicity compared to 
cisplatin [76]. SPI-77 (Alza Pharmaceuticals) is another liposomal cisplatin 
formulation. Preclinical studies in tumor-bearing mice indicated higher antitumor 
activity in contrast to cisplatin with higher cumulative doses of SPI-77 being well 
tolerated [77].  
There are four main variations of liposomal delivery systems: conventional liposomes, 
ligand-targeted liposomes, sterically-stabilized liposomes, and a combination of the 
above. The first generation is the conventional liposomes which consist of a lipid 
bilayer that can be composed of anionic, cationic, or neutral phospholipids and 
cholesterol.  
21 
 
Table 1- 2: Therapeutic areas covered by liposomes-based products. 
 
 
Area Clinical 
Products  
Active Agent Indication 
Cancer therapy Doxil®  Doxorubicin Ovarian, breast cancer, Kaposi’s sarcoma 
DaunoXome® Daunorubicin AIDS-related Kaposi’s sarcoma 
Depocyt®  Cytarabine/Ara-C Neoplastic meningitis 
Myocet®  Doxorubicin breast cancer 
Mepact®  Mifamurtide High-grade, resectable, non-metastatic 
osteosarcoma 
Marqibo®  Vincristine Acute lymphoblastic leukaemia 
Onivyde™  Irinotecan metastatic adenocarcinoma of the pancreas 
Fungal diseases Abelcet®  Amphotericin B Invasive severe fungal infections 
Ambisome® Amphotericin B Presumed fungal infections 
Amphotec®  Amphotericin B Severe fungal infections 
Analgesics DepoDur™ Morphine sulfate Pain management 
Exparel® Bupivacaine Pain management 
Viral vaccines Epaxal®  Inactivated hepatitis A virus  Hepatitis A 
Inflexal®V  Inactivated hemaglutinine of Influenza virus strains A 
and B 
Influenza 
Photodynamic 
therapy 
Visudyne®  Verteporphin Choroidal neovascularisation 
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Research on the clinical significance of conventional liposomal delivery showed 
improvement of the therapeutic index of encapsulated drugs, such as doxorubicin. The 
toxicity of drugs in vivo was also reduced by alteration of the pharmacokinetics and 
biodistribution, improving drug delivery to diseased tissue in contrast to free drug.  
To enhance liposome stability and improve the blood circulation time, sterically-
stabilized liposomes were developed. The hydrophilic polymer, polyethylene glycol, 
has proved to be the best choice to obtain sterically-stabilized liposomes. The 
formation of a steric barrier enhances the efficiency of encapsulated drugs by 
minimizing in vivo opsonization with serum components, and the fast recognition and 
uptake by the reticuloendothelial system which decreases the side effects [78].  
Ligand-targeted liposomes have the potential for site specific delivery of drugs to 
selected cell types or organs in vivo, which are characterized by selective expression 
or over-expression of specific ligands at the site of disease [79].  Several types of 
ligands are available, such as carbohydrates, antibodies, and peptides/proteins. 
Monoclonal antibodies, used to create immunoliposomes, are some of the most 
versatile ligands that can be attached to liposome surfaces. Monoclonal antibodies are 
used owing to their stability and higher binding affinity due to the presence of two 
binding sites on each molecule [80].  
Steric stabilization strongly affects the pharmacokinetics of liposomes, with reported 
half-lives ranging from 2 to 24 h in rodents (mice and rats) and as high as 45 h in 
humans, based on the characteristics of the coating polymer and particle size [81]. 
Whilst coating liposomes with polyethylene glycol results in extended circulation 
times, generally, as a drug delivery platform, liposomes provide a more dynamic and 
adaptable technology for improving the systemic effectiveness of therapeutics in 
many diseases [82].  
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Of late, liposome research has focused on the development of strategies to increase 
the activity of conventional liposomes to facilitate intracellular delivery of the 
encapsulated molecules. This resulted in the development of an improved form of 
liposomes called pH-sensitive liposomes (PSL). These liposomes are stable at 
physiological pH (pH 7.4) but undergo destabilization and acquire fusogenic 
characteristics upon acidification, leading to the release of their contents into the 
cytosol. Different types of PSL have been reported in the literature, based on the 
mechanism of triggering pH sensitivity [83-85].  
Commonly established methods include  blending PE or its derivatives with 
compounds containing an acidic group (e.g. carboxylic group) that functions as a 
stabilizer at neutral pH [86]. Different studies describe the use of synthetic fusogenic 
peptides/proteins, and novel pH-sensitive lipids either included or encapsulated in the 
lipid bilayer and attachment of pH-sensitive polymers with liposomes [87, 88]. 
Liposomes need to be stable in biological fluids and have long circulation times when 
administered intravenously, allowing them to reach target cells (such as tumor cells) 
and mediate cytoplasmic delivery [85]. The use of lipids with high transition 
temperatures, such as hydrogenated soya PC (HSPC), distearoylphosphatidylcholine 
(DSPC), the incorporation of cholesterol and lipid conjugates, such as 
phosphatidylethanolamine–poly(ethylene glycol), has led to a significant decrease in 
leakage of the encapsulated drugs through the circulation or in the extra-cellular 
environment [89]. These lipids also reduce non-specific interactions between the 
liposomes and serum proteins (opsonins), therefore, avoiding liposome clearance by 
the cells of the RES. Moreover, the usage of liposomes of size < 150 nm can lead to 
the increase of the circulation time [90].  
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1.5.3. Advantages of liposomes for inhalation  
Local application of liposomes has been extensively investigated, including the 
pulmonary path for controlled delivery of drug to the lung. The development of 
liposomal formulations for aerosol delivery has expanded the potential for more 
effective utilization of an array of potent and effective drugs. Liposomal aerosols in 
pulmonary therapy are believed to overcome some of the problems associated with 
conventional chemotherapy due to their capability to: (1) act as a solubilization matrix 
for agents with different solubility, whether hydrophobic, hydrophilic or a 
combination of both; (2) act as a biodegradable  sustained release reservoir; and (3) 
enable intracellular delivery of drugs, specifically to alveolar macrophages [91]. 
Consequently, liposomes can improve pulmonary residence time, prolong local 
therapeutic drug levels, reduce pulmonary toxicity, and result in high intracellular 
drug concentrations. Cumulatively, this will result in a decreased systemic spill-over 
of drugs and an increase in their potency. Moreover, liposomes are considered 
promising nanocarriers because of their good structure compatibility with lung surface 
cells since they are prepared with PLs endogenous to the lung as surfactants [92].  
The success of liposomes as DDS is reflected in the number of liposome-based 
formulations that are commercially available or are currently under clinical research 
[73]. There are many disease states which could potentially benefit from treatment 
with aerosolized liposome-encapsulated drugs. A number of possible therapies 
employing inhaled liposomes have been investigated. The majority of studies focus 
on the potential for targeting the lung with drugs for a local effect. Cancer was the 
most extensively researched area in respect of clinically approved liposome products 
[73, 93]. Some drugs with advantageous local effects may have toxic systemic effects 
and their pulmonary absorption would be undesirable. (e.g., cytotoxic anti-cancer 
25 
 
drugs). Therefore, drug formulation plays an important role in creating an effective 
inhalable treatment. It is important have a drug that is pharmacologically active, but 
also efficiently delivered into the lungs to the appropriate site of action and will remain 
in the lungs until the desired pharmacological effect occurs [73].  
Many studies have shown the high biocompatibility and biodegradability of liposomes 
as drug carriers in inhaled formulations (Table 1- 3) [71]. Historically, liposomes were 
recommended as surfactant replacement therapy in patients with respiratory distress 
syndrome. More recently, pulmonary surfactants based on mixtures of phospholipids 
have been commercialized (e.g. Survanta ®) as prophylaxis against respiratory distress 
syndrome in neonates [94]. Myers et al., have shown that chronic inhalation of HSPC 
liposomes caused no histologic changes of the lung or untoward effects on general 
health or survival of animals [95].  Prolonged nebulization of higher concentrations 
of HSPC (up to 150 mg/ml), acted as a local sustained release reservoir, and were safe 
and nonirritating to the lung of sheep. Also, several studies using human volunteers 
have confirmed the safety of liposomal formulations for inhalation [71, 73, 96]. Drugs 
encapsulated in liposomes are safe for pulmonary delivery since liposomes can control 
the drug release, hence decreasing the local drug concentration available to exert side 
effects  [97]. Early studies showed the safety of drugs in liposome formulations given 
by inhalation. In vitro assessment of transferrin-conjugated doxorubicin-loaded 
liposomes showed greater cytotoxicity toward cancerous human pulmonary epithelial 
cell lines (Calu-3 cell line, A549 cell line, and 16HBE140 cell line) in comparison to 
non-cancerous human AT I/AT II cells in primary culture [98]. This study suggested 
that such DDS might have the potential to selectively deliver cytostatic drugs to sites 
of lung cancer by inhalation.  
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Table 1- 3: In vivo studies of aerosolised liposomal formulations for treating lung cancer [71]. 
Therapeutic 
agent 
Delivery device Major 
ingredient 
Subject Mass median 
aerodynamic 
diameter (μm) 
Study 
phase 
Reference 
Cisplatin PARI LC Star jet nebulizer DPPC Human 3.7 Phase I  [99] 
9-nitro-
camptothecin 
 
AeroMist nebulizer DLPC Human 1–3 Phase I/II [100], [101] 
AeroTech II nebuliser  DLPC Animal (mice) 1.2–1.6 –  [102], [103] 
AeroMist nebulizer DLPC Animal (mice) 1.2 –  [104] 
Interleukin 2 Puritan Bennett twin jet nebuliser DMPC Human & Animal  2.0 Phase I [105], [106] 
Paclitaxel AeroMist nebulizer DLPC Animal (mice) 2.2 – [107, 108] 
Doxorubicin Collison nebuliser connected to four-
port, nose-only exposure chambers 
DLPC Animal (mice) – – [48] 
Doxorubicin Collison jet nebulizer EPC-Chol, 
DSPE-PEG 
Animal (mice) – – [109] 
Camptothecin Aerotech II nebulizer DLPC Animal (mice) 1.6 – [110] 
DPPC = dipalmitoylphosphatidylcholine; DLPC = dilauroylphosphatidylcholine; DMPC = dimyristoylphosphatidylcholine; EPC-Chol = egg phosphatidylcholine 
with cholesterol; DSPE-PEG = pegylated distearoyl phosphatidylethanolamin 
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Zhang et al. studied the in vitro release, in vivo distribution (in mice) and severity of 
damage (in rat lungs) following intratracheal instillation of 9-nitrocamptothecin (9-NC) 
liposomes. The results showed that 9-NC liposomes act as local sustained release 
reservoir and were safe and non-irritating to the lungs [111].  
The safety of drugs in liposome formulations given by inhalation is not limited to 
anticancer agents. Many early studies have demonstrated the safety of liposomes for 
pulmonary administration of antimicrobial agents, genes, and antidiabetic drugs. For 
example, no adverse effects on the function or histology of the lungs were reported once 
liposome-pDNA complexes were aerosolized to the lung [112]. Steroids are usually used 
as anti-inflammatory agents in prophylaxis for asthma. Researchers have demonstrated 
that beclomethasone liposome aerosol was well tolerated when given in therapeutic doses 
to humans [113]. 
1.6. Physicochemical characteristic of pulmonary liposomes 
The pulmonary administration of liposomal formulations is very promising, offering the 
benefit of improved drug concentrations at the site of action.  Nevertheless, specific care 
must be given to the stability of liposomes, as they may be exposed to physical and 
chemical changes which can result in leakage of the encapsulated agents. Several 
parameters are key to the successful generation of stable liposome aerosols [114]. 
1.6.1. Phospholipid Composition and Mean Size of Liposomes 
The lipid composition and mean size of liposomes have been found to affect the stability 
of liposomes during nebulization. Niven and co-workers studied the parameters that 
influence the release of carboxyﬂuorescein from liposomes after nebulization. They 
showed that a reduction in liposome mean size from 5 to 0.2 µm led to a lower release 
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rate of carboxyﬂuorescein from liposomes prepared with a lipid mixture of soy 
phosphatidylcholine and dipalmitoyl phosphatidylglycerol [115]. Also, Taylor et al, came 
to a similar conclusion in their studies on size reduction of liposomal vesicles, prepared 
with cholesterol and phosphatidylcholine by extrusion techniques [116]. The 
phospholipid composition controlling the rigidity of liposomal membranes is a significant 
parameter that affects the leakage of encapsulated drugs from the liposome vesicle, 
mainly when the temperatures through nebulization are higher than the phase transition 
temperature (Tm) of the phospholipid mixture. Different studies have shown that 
nebulization of liposomes at temperatures above the Tm of the phospholipids resulted in 
an increased release of encapsulated drug and increased  rigidity of the bilayer, either by 
insertion of cholesterol or by using more rigid phospholipids, leading to the formation of 
liposomes which were more resistant to nebulization [117]. 
1.7. Technical concerns of using aerosolizable particles for 
pulmonary delivery   
Nanoparticles are attractive for pulmonary delivery due to their important and unique 
features, such as their surface to mass ratio which is larger than that of other particles and 
their ability to adsorb and carry other compounds. However, NPs, in dry form do not 
deposit efficiently in the deep lungs leading to the exhalation of most of the inhaled dose. 
To solve this problem, particulate systems combining NPs into micron-scale structures 
have been developed; such as  agglomerated NPs, embedding NPs within an inert 
‘microcarrier’,  porous nanoparticle-aggregate particles [118] and nanocomposite 
microparticles (NCMPs) [119]  as a dry powders. These systems are designed to dissolve 
upon contact with lung lining fluids hence releasing the NPs with encapsulated drug  from 
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the inert carrier [120]. Consequently, in order to increase the amount of drug deposited 
in the lung, and hence the amount of drug offered for absorption, it is essential to 
overcome the natural defense barriers of the lung [121]. 
1.7.1. Particle Deposition in the Lung  
There are three main deposition mechanisms, inertial impaction, gravitational 
sedimentation, and Brownian diffusion that cause deposition of particulate matter in the 
lung. Inertial impaction arises after a particle travelling in an air stream is unable to follow 
a change in direction and the momentum of the particle causes it to remain in the original 
direction of motion, and impact on the respiratory airway’s wall. This mechanism occurs 
in the upper respiratory tract and is accountable for the deposition of large and/or dense 
particles (e.g., particles >5 µm in diameter) travelling at a high velocity. While, very small 
particles (e.g., particles ˂1 µm in diameter) will typically deposit through the mechanism 
of Brownian diffusion, as a result from the random motions of the particles produced by 
their collisions with gas molecules and this motion can lead to contact and deposition in 
the alveolar region, where there is very low airflow. Particles of an intermediate size (1–
5 µm) will evade deposition by inertial impaction and will instead deposit by gravitational 
sedimentation, where the settling rate is dependent on the particle size, density, in addition 
to its residence time in the airway. This mechanism occurs in the central and peripheral 
regions of the lung. Therefore, for effective pulmonary deposition, the aerosol must 
include particles 1–5 µm in diameter. Moreover, central and peripheral deposition can be 
improved by patient breathing techniques, such as a slow, deep breath followed by a 
breath hold, to maximize deposition by gravitational sedimentation and Brownian 
diffusion and minimize deposition by inertial impaction [79, 122, 123]. 
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1.7.2. Clearance Mechanisms  
After the deposition of inhaled drugs inside the lung, there are several physiological 
barriers to overcome before absorption can take place in the respiratory epithelium, and 
consequently drug action, can occur. The first barrier is a thin layer of mucus, about 5 µm 
deep that covers the walls of the tracheobroncial airways. The function of this mucus, in 
addition to hydrating the pulmonary epithelium, is removal of entrapped particulate 
matter via mucociliary clearance. Although the unciliated alveolar airways are not 
covered in mucus, phagocytic macrophages exist in this region, engulfing particulate 
matter and transported to the ciliated areas of the respiratory tract for elimination by 
mucociliary clearance. Also, mast cells present in the tracheobroncial and respiratory 
airways release protease enzymes, and several other enzymes, such as esterases, 
peptidases, are present in the lung and exist as an extra barrier to susceptible compounds 
[124, 125]. 
1.8. Methods of preparation of liposomal dry powders for 
inhalation 
1.8.1. Freeze-drying  
Freeze drying is a two-step procedure; first freezing of the sample then removing the 
water by sublimation under vacuum. This method can prevent hydrolysis of the lipids and 
physical degradation of the vesicles during storage. On the other hand, the freeze-drying 
method itself can affect the final product and consequently influence the liposome 
stability and induce changes in the vesicle size and loss of the encapsulated drug. The 
freezing rate is a very important step and the impact of slow and quick freezing was 
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reviewed by Van Winden et al. [126] who  demonstrated that successful drug retention 
during freeze drying is mostly dependent on the lipid bilayer composition. Moreover, a 
slow freezing rate is advantageous. This is can be explained by the improved membrane 
recovery from deformations during slow freezing. These deformations are due to the 
osmotic pressures, which are formed by freeze-concentration. Finally, the resultant dried 
powder must be processed, usually by jet milling, to decrease its particle size so that it is 
suitable to use for DPI.  However, the frictional contact between particles during jet 
milling can lead to liposomal disruption. Moreover, freeze-drying is an energy and time-
consuming technique. Excipients such as disaccharides can been added to protect the 
liposomes [127]. 
1.8.2. Spray drying  
Spray drying (SD) is a one-step technique which transforms liquid feedstock into a dried 
particulate.  The liquid feedstock can be a suspension, solution or emulsion. The first step 
in SD is the atomization of the liquid through a nozzle followed by the sprayed gas mixing 
in the drying compartment. The droplet size reduces with evaporation until the droplets 
eventually turn into particles. The dried particles are then separated from the gas by a 
cyclone [128]. One advantage of SD compared to other drying methods is the possibility 
to design the resulting product in terms of shape, particle size, moisture content, and 
density. This  offers a way to produce microparticles appropriate for the pulmonary 
delivery of drugs since  pulmonary deposition patterns are highly dependent on particle 
size due to the complex anatomy of the lungs that is significant for the particle movement 
patterns in the airways (Figure 1- 7) [129].  
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Goldbach et al. studied the SD of liposomes to produce particles appropriate for 
pulmonary delivery. Atomization was achieved by a rotary atomizer and a pneumatic 
nozzle and produced particle sizes of 3.5 µm and 7.1 µm. The liposome mean size was 
not affected by the SD process, the phospholipids were not oxidized or hydrolyzed [130] 
and SD had no effect on the encapsulated drugs.  Goldbach and others found only a slight 
decrease in the size of redispersed powders, when atropine sulphate liposomal dispersions 
were spray dried in the presence of 10% lactose [130].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1- 7: A diagram of the effect of aerosol particle size on the site of 
deposition in the airways. 
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1.8.3. Spray freeze drying 
The spray freeze-drying process can be divided into two separate steps: spray-freezing 
into a cryogenic liquid and lyophilization.  Spray freeze-drying has been used to produce 
dry forms of poorly water-soluble drugs and to transform suspensions of liposomes into 
dry-powders using adjuvants such as lactose, sucrose, and mannitol. One example is the 
production of a liposomal powder formulation containing ciprofloxacin for pulmonary 
drug delivery where, after reconstitution of the powder, spontaneous in vitro formation 
of liposomes in pulmonary fluid occurred. The main advantage of this process is the 
improved mass median aerodynamic diameter (MMAD) [131]. The limitations of the 
method are the use of expensive cryogenic fluids, which can be technically impractical, 
and it is a time consuming and expensive method [132].  
1.8.4. Supercritical fluid 
Supercritical fluids (SCF) are compressed liquids or gases above their critical 
temperatures and pressures and have the combined advantages of both gases and liquids. 
Supercritical fluids have many attractive properties such as providing mild conditions for 
pharmaceutical processing, which is advantageous for labile drugs[133]. Moreover, 
simple and convenient SCF processes have been used to produce liposomes eliminating 
the problems involved in conventional preparation. Commonly used SCF include carbon 
dioxide, propane, nitrous oxide, acetone, propane, chlorodifluoromethane, diethyl ether, 
water, or mixtures. The SCF used in most studies is carbon dioxide because it is cost 
effective, nontoxic, nonflammable and has an accessible critical point of 31°C and 74 bar 
that makes it appropriate for processing thermolabile agents.  [134]. There are several 
studies reporting the preparation of liposomes using SCF-CO2 [135]. Liposomes 
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formulations were produced using CO2 as a substitute for organic solvents by 
depressurizing the supercritical phase into water. At pressures over 200 bar, spherical 
liposomal vesicles with good uniformity were attained [136]. Cyclosporin A and 
Amphotericin B liposomes are the main DDS formulated using SCF [134]. Frederiksen 
et al [137] used  SCF-CO2 to prepare liposomes containing lipid and cholesterol dissolved 
in organic solvent, into the aqueous phase, which produced small unilamellar vesicles 
20–50 nm in size. Otake et al [138] developed an enhanced supercritical reverse-phase 
evaporation process to evade the use of organic solvent in liposome formulation and 
improve the stability and drug-loading efficiency.  
1.9. Aerosol delivery device options  
There are three different categories of inhalation technologies including nebulizers, 
metered dose inhalers (PMDIs), and DPIs. 
1.9.1. Nebulizers  
There are three types of commercially available nebulizers: air jet, ultrasonic, and 
vibrating mesh. Air jet nebulizers depend on compressed gas passing through a nozzle to 
produce a negative pressure above the nebulizer fluid, which causes liquid filaments to 
form and collapse into aerosol droplets due to the liquid’s surface tension [139]. 
Ultrasonic nebulizers use a piezoelectric crystal which vibrates at high frequency under 
the nebulizer fluid in order to create a fountain of liquid that releases aerosol [139, 140]. 
The third type, namely vibrating-mesh nebulizers, has lately been commercialized.  Mesh 
nebulizers use micropump technology for aerosol production. They force liquid 
medications through several apertures in a mesh to produce an aerosol. As small and 
portable nebulizers that are powered by either rechargeable battery or electricity, they 
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have silent efficient operation, short treatment times, and minimum residual volume. 
Advantages of mesh nebulizers include consistent and improved aerosol generation 
efficiency, a mainly fine-particle fraction reaching into the peripheral lung, and the 
capability to nebulize low drug volumes [141-143].  
The size of the pore, in the aerosol chamber and the reservoir, in addition to the output 
rate of mesh nebulizers, can be adjusted for different drugs in order to improve aerosol 
drug delivery to patients[144]. Comparisons of ultrasonic and mesh nebulizers confirmed 
similar drug delivery in simulated ventilator-dependent patients [143].  
1.9.1.1. Aerosolisation of Liposomes 
One of the parameters that affects the suitability of liposomes for inhalation is the method 
of application. Most liposomal formulations are nebulized to produce an inhalable aerosol 
cloud using different types of nebulizers. However, effective drug delivery might be 
affected by disintegration and instability of the liposomes by the high shear forces applied 
by the nebulizers leading to fragmentation of the liposomal bilayers and leakage of 
encapsulated drug [145].  
An important issue for nebulization of liposomes is the lipid concentration and the 
corresponding aerosol output rate. Different studies have shown a direct correlation 
between droplet size, phospholipid concentration and viscosity, when using air-jet 
nebulizers for aerosolizing liposomes. A decrease in the aerosol output rate was detected 
when the liposomal size was greater than 2.5 µm. Increasing the liposomes mean size 
decreased the number of liposomes in the aerosolized droplets [115]. Thus, the 
nebulization of large liposomes will decrease the total liposomal aerosol output and 
influence the stability of the encapsulated drug [116].  Elhissi et al,  found that MLVs 
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entrapping salbutamol sulphate were unstable during jet nebulization and stability was 
not enhanced when vesicles were extruded before nebulization [146]. The use of very 
viscous ﬂuids led to termination of nebulization in the Omron Micron Air whereas in the 
Aeroneb Pro, an irregular aerosol generation was observed [147]. 
Liquid liposomal formulations are associated with some stability issues during 
aerosilization. Physical instabilities such as aggregation and fusion affect the properties 
of liposomes and may cause leakage of the encapsulated drug [148]. Therefore, to 
overcome these problems, dry powder formulations have been developed for pulmonary 
drug delivery. Several strategies have been used to increase the stability of liposomes 
which are freeze-drying (lyophilization), and spray drying technologies. 
Several nebulizers have been tested to report their suitability for pulmonary 
administration of liposomes. With air-jet nebulizers, the droplet size is affected by the 
pressure of the compressed air and the structure of the nebulizer. Jet nebulizers have been 
shown to be effective for aerosol droplet deposition in lung tissues. Mostly, the size of 
the droplets in which the liposomes are dispersed is a significant issue in lung deposition. 
The mass median diameters (MMDs) generally range from 2 to 5 µm, will be deposited 
into the lower respiratory tract or the alveolar system, with an air pressure of 20 to 30 psi 
[146].  
With ultrasonic nebulizers, aerosols are produced using high frequency ultrasound waves. 
The higher the frequency, the smaller the droplet size because of the heat generated 
through the process of atomization. During this process, the stability of labile agents can 
be negatively affected or encapsulated materials could be released from liposomal 
formulations [149].  
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The vibrating mesh technology is appropriate to nebulize sensitive agents such as 
peptides, proteins, nucleic acids or liposomal formulations, as high temperatures are 
minimized in contrast to ultrasonic nebulizers. This is owing to the lower operating 
frequency and since the energy needed for the nebulization is used [147]. 
Mesh nebulizers have demonstrated higher efficiency than jet nebulizers and can deliver 
higher drug doses to patients. Though human studies with mesh nebulizers are limited, in 
vitro studies confirmed approximately 2-3 times higher lung deposition with mesh 
nebulizers in contrast to jet nebulizers [150, 151]. Owing to the higher efficiency of mesh 
nebulizers, the doses of drug formulations may need to be adjusted to avoid the 
development of side effects because of overdose. Thus, patients need to be be monitored 
during treatment for clinical responses and side effects. 
Elhissi et al have shown that an ethanol-based method to producing liposomes can be 
used to prepare a salbutamol sulphate formulation with improved drug output and 
inhanced fine particle fraction (FPF) compared to a conventional solution of the drug 
when nebulization was performed using the vibrating mesh nebulizer [152]. 
The vibrating-mesh nebulization using the customized large aperture mesh nebulizer had 
a less disruptive effect on liposomes and produced a higher output rate in comparison 
with the air-jet nebulizer [146].  
 
1.9.2. Pressurized-metered dose inhaler  
pMDIs are robust devices containing a drug dissolved or dispersed in a liquefied 
propellant that upon actuation with coordinated inspiration delivers a precise dose, 
generally with an aerodynamic particle size of less than 5 microns. The propellant rapidly 
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evaporates due to its high vapor pressure, leaving an accurate dose of the aerosolized drug 
particles to be inhaled by the patient. 
They are inexpensive and pocket-sized devices but are not very efficient. They are 
associated with poor lung deposition and hence are generally only appropriate for 
molecules that are potent at low doses [132].  An approach to delivering liposomes using 
pMDIs was testified by dissolving the phospholipid in chlorofluorocarbons (CFC) 
propellant in which drugs like Salbutamol and co-solvents like ethanol are included. 
However, there are concerns about using pMDIs clinically, due to the limited dose 
reaching the deep lung and environmentally, because CFCs contributed to the depleting 
the ozone layer. The ozone-depleting effect of CFCs resulted in the introduction of safer 
alternative propellants, namely hydrofluoroalkanes, in which phospholipids have very 
limited solubility. However, lipid-based formulations for use in pMDIs have been made 
by dispersing phospholipids in PEG-phospholipids followed by the delivery of the 
subsequent in situ formation of liposomes in the aqueous environment of the impinger 
[154]. Furthermore, the development of liposomal formulations for delivery via pMDIs 
has major limitations such as complicated formulation, stability, and poor FPF of the 
aerosolized dose [153]. Moreover, the inclusion of co-solvents in phospholipid 
formulations may be deposited in the lung, also contributing to limitations of pMDIs [153, 
154]. 
1.9.3. Dry Powder Inhaler     
Among the three categories of inhalation technologies, dry powder inhalers (DPI), are the 
most extensively studied for the treatment of several lung diseases and pathological 
conditions. Each type of delivery device has unique strengths and weaknesses therefore 
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DPIs were introduced to overcome some of the weaknesses associated with nebulizers 
and pMDIs [155]. DPIs stand out because of the stability of drugs and formulations [156].  
DPIs are portable, breath actuated devices that need minimal patient coordination 
between breathing and actuation. Although, Nebulizers have been used extensively for 
the delivery of liposomes [92, 157], liposomal DPIs have many advantages for pulmonary 
administration with respect to; reduced toxicity, increased potency, controlled delivery, 
uniform, local drug deposition, high dose capacity, propellant-free nature, patient 
compliance, and stability [154]. Using powdered medicines offers a benefit especially for 
the delivery of poorly water-soluble, peptide and protein drugs [158]. 
The preparation of liposomes for DPI has been investigated using several drying 
technologies such as freeze drying, SD, or spray freeze drying. For any of these 
technologies, the challenge is to stabilize the liposome vesicles to prevent agglomeration 
or membrane rupture, minimize release of the encapsulated drug throughout the 
processing steps, and ensure that the vesicle structure is maintained upon hydration in the 
lung fluid. One approach that avoids drying of liposomes, and therefore, their potential 
rupture, is to generate the liposomes in situ in the airways of the lung from the individual 
dried components (e.g., lipids, drug and a powder dispersing agent such as lactose).  It is 
expected that hydration of the powdered lipid particles would occur in the aqueous fluid 
of the lung following inhalation of the proliposome powder  [159]. Although the 
encapsulation efficiency after reconstitution was 100% for the cationic CM3 peptide and 
96% for ciprofloxacin, this approach may not be possible for every liposomal product 
[98].  
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Another approach is SD of agents in liposome formulations of small aerodynamic size 
particles (i.e. high FPF), and it was predicted that the rehydration of liposomes would 
occur after the deposition of the powder in the aqueous environment of the lung. Joshi et 
al studied the delivery of liposomal budesonide and liposomal ketotifen DPI by blending 
the lactose carrier with preformed liposomes. They found that DPI of liposomes was 
successful when delivered as an aerosolized DPI to the required site in the lungs [160, 
161].  
Liposomal dry powders of N-acetylcysteine were developed for pulmonary 
administration. Liposomes were spray dried using lactose (10%, w/w) as a drying 
adjuvant. Liposomal dry-powders recovered the nanometric size of the original dispersion 
after their redispersion in aqueous medium and the powders presented aerodynamic 
diameters of about 7 μm and respirable fractions above 30%, indicating suitable 
properties for pulmonary use [162].  
The formulation of liposomes as dry powder for inhalation is a promising method for 
NSCLC treatment. 
 
1.11. Thesis Aim and objectives  
To design, formulate and characterize nanocomposite microparticles encapsulating AFT 
as a treatment for NSCLC by dry powder pulmonary delivery.  
 
To meet the aim of the thesis a systematic study was designed considering the following 
objectives:  
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1) 1) Optimization of AFT loaded liposomes NPs prepared by the thin film hydration 
technique.  
a. Optimization of NPs in term of lipid ratios, size, zeta potential, and encapsulation 
efficiency.  
b. Development and validation of an HPLC method for in vitro analysis of AFT.   
c. Evaluation of the stability of the liposomal dispersion. 
2)  Investigation of the toxicity and efficacy of the optimized liposomal NPs.  
a. Evaluation of the cytotoxicity of the optimized AFT-liposomal NPs formulations 
on NSCLC cells.  
b. Investigation of the therapeutic effect of AFT in lung cancer cells using proteomic 
analyses.  
3) Incorporation of NPs into NCMPs via spray drying  
a. Optimization of NCMPs formulations in term of size, zeta potential, morphology 
yield% comparing different carrier materials. 
b. Assessment of the in vitro aerosolisation properties, release and lung cell 
toxicity.  
c. Assessment of the stability of NCMPs. 
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2.1. Introduction 
Liposomal drug delivery systems have been reported to improve the administration of 
chemotherapeutic agents in the treatment of lung cancer and inhibition of metastases 
when compared to other DDS [71]. Liposome encapsulation can increase the antitumor 
efficacy of the incorporated drugs by providing more selective delivery and/or targeting 
to the tumor tissue, while in other cases, toxicity is decreased by avoidance of critical 
normal tissues [72]. 
The physicochemical properties of liposomes can highly affect their in vivo stability and 
kinetics.  An important parameter that influences passive targeting through the enhanced 
permeability and retention (EPR) effect is the size of the liposomes. The accumulation of 
liposomes in the tumor depends on the size of the endothelial gaps lining the tumor 
capillaries. To apply the EPR effect, the liposomes should generally be <200 nm [163]. 
The composition and charge on the surface of liposomes are other parameters that 
influence passive targeting. Cationic vesicles have been shown to provide higher 
encapsulation efficiencies due to electrostatic interactions [54]. Cationic liposomes (CL), 
prepared from at least one cationic phospholipid enable  cellular uptake by electrostatic 
absorptive endocytosis due to the negative charge on the cell membrane [164]. Although 
these liposomes have the capability of intracellular delivery, they are associated with 
drawbacks such as rapid clearance from the reticuloendothelial system (RES) and 
cytotoxicity  [165, 166]. The toxicity associated with the use of cationic lipids  can 
severely limit clinical applications [167]. 
Another approach to improve therapeutic efficiency of conventional liposomes is the use 
of local triggers such as enzymes or pH for site-specific release of therapeutics from 
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liposomes or the use of specific lipid compositions [168]. The use of pH-sensitive 
liposomes (PSL) is one strategy to increase the activity of conventional liposomes. These 
liposomes are destabilized in the acidic environment of the endocytotic pathway as they 
contain pH-sensitive lipid components. Therefore, the encapsulated drug is delivered to 
the intracellular bio-environment by destabilization or fusion with the endosomal 
membrane. PSL are usually composed of a neutral cone-shaped lipid 
dioleoylphosphatidyl-ethanolamine (DOPE) and a weakly acidic amphiphile, for 
example cholesteryl hemisuccinate (CHEMS) [169]. The fusogenic performance of these 
liposomes is due to the DOPE present in the lipid layer that does not form a bilayer 
structure, once dispersed in aqueous media, but forms a hexagonal structure. Other lipids 
such as N-succinyl-DOPE [170], or dioleoylphosphatidylcholine (DOPC) [171]   can also 
be incorporated to induce pH sensitivity. All these lipids have a negatively charged group, 
which can be neutralized on the acidic endosome, resulting in destabilization, fusion with 
endosomal membrane and content release [172]. PSL rapidly become destabilized on 
acidification in the tumor tissue and the applications of PSL can be restricted because of 
their recognition by the phagocytes of the RES resulting in a very short circulation half-
life of these carriers. To overcome RES uptake and prolong circulation time, the inclusion 
of PEGylated phospholipids in liposome composition is recommended. Moreover, the 
development of nano-size liposomes can contribute to an increase in circulation time and 
enhance the uptake by target cells [173]. The therapeutic effectiveness of PSL supports 
their  commercial utility especially in cancer treatment [85]. A bio-distribution study 
comparing PEGylated (stealth) PSL containing cisplatin and free cisplatin in solid tumor 
bearing mice was reported. The results showed that stealth PSL enhanced the 
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bioavailability of cisplatin in the tumor and retention of stealth PSL by the kidney 
indicated the usefulness of this carrier to reduce cisplatin toxicity [174].  
Depending on the application of the liposome, a variety of production methods may be 
used to attain the desired properties. Size, lamellarity and the homogeneity of the 
liposomal formulation are all end goals that impact the choice of preparation method. The 
most widely used method is the thin-film hydration method, also named hand shaking 
method or Bangham method [175]. For preparing liposomes, phospholipids are 
distributed in a thin film on the surface of glassware by dissolving a mixture of 
phospholipids in an organic solvent, typically chloroform, and later evaporating the 
solvent. The addition of an aqueous buffer under conditions of agitation or vortexing 
results in the production of liposomes. The temperature needs to be kept above the phase 
transition temperature of the phospholipids.  Most liposomes are then extruded through 
membranes under pressure in order to get a homogenous size distribution [70]. Liposomes 
with diameters between 100-200 nm are most desirable as in this size range they are able 
to accumulate in the affected tissues. This size range of liposomes also does not induce 
an immune response but are of sufficient size to carry an appropriate concentration of the 
desired drug [176, 177].  
Simple approaches to decreasing liposome size include vortexing of the rehydrated lipid 
film or sonication. Two different sonication devices can be used. Probe sonication is one 
choice, but has a crucial disadvantage in that metal parts from the probe tip can end up in 
the liposome formulation [178]. An alternative is the use of a bath sonicator [179]. 
Homogenization can also be used to reduce the liposome size.  Brandl et al., produced 
small unilamellar vesicles with a narrow size distribution and a size of 25 – 50 nm  using 
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a high-pressure homogenizer [180]. The French press extrusion is another approach to 
generating liposomes of a definite size. Hamilton et al., used a French pressure cell to 
extrude liposomes at 20 000 psi through a small orifice. After only a single pass, 70 % of 
the liposomes built a homogenous population [178].  
On a laboratory scale, there are two commonly used techniques: the sonication techniques 
described above and filter extrusion using polycarbonate membranes with defined pore 
sizes. This method has several advantages; it yields liposomes with relatively 
homogeneous size distributions and is reproducible. A liposome suspension is extruded 
many times through a membrane with a defined pore size. In order to achieve a smooth 
extrusion, the temperature of the liposome dispersion must be above the phase transition 
temperature of the phospholipids or the membrane will clog and break.  Berger et al., 
reported that extrusion through big filter pores (e.g. 800 nm) results in vesicles smaller 
than the filter pore size. Another determining factor is the number of extrusions [181]. 
With increasing extrusions through the same membrane, the size distribution becomes 
more uniform. A disadvantage of classical extrusion procedures is the limited batch size 
[182].  
2.2. Aim 
This study aims to formulate and evaluate liposomes nanoparticles (NPs) encapsulating 
afatinib (AFT) into CL and PSL compared to NL (control liposomes) for the design of an 
efficient anticancer delivery system.  The main objectives of research were: to optimize 
liposome formulations in terms of; lipid ratio, particle size, polydispersibilty index, zeta 
potential, AFT encapsulation efficiency, and liposome stability. To achieve this, a liquid 
chromatography (HPLC) assay was developed for AFT quantification.  
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2.3. Materials and methods  
2.3.1. Materials 
AFT (99.8% purity) was purchased from Green Stone Swiss Co., Limited. 1,2-distearoyl-
sn-glycero-3-phosphocholine [18:0] (DSPC), 1,2-dioleoyl-sn-glycero-3-
phosphoethanolamine [18:1] (DOPE), 1,2-dioleoyl-sn-glycero-3-phosphocholine [18:1] 
(DOPC), and Cholesteryl hemisuccinate (CHEMS), was purchased from Avanti Polar 
Lipid. 1,2-dioleoy-3-trimethylammonium-propane Chloride salt (DOTAP) were kindly 
gifted by Avanti Polar Lipid. Phosphate buffered saline powder, pH 7.4, HEPES (4-(2-
hydroxyethyl)-1-piperazine ethane sulfonic acid), Triton X-100, Triethylamine, Sodium 
hydroxide pellets, and Tween 80 were purchased from Sigma-Aldrich, Saint Louis, USA. 
All other reagents and chemicals were of analytical grade. 
 
2.3.2. Methods  
2.3.2.1. Preparation of conventional liposomal nanoparticles  
Afatinib loaded liposomes NPs  were prepared by a thin film hydration method [183] 
(Figure 2- 1).  To prepare conventional non-targeting liposomes (NL), a mixture of 1, 2-
distearoyl-sn-glycero-3-phosphocholine [18:0] (DSPC): 1,2-dioleoyl-sn-glycero-3-
phosphoethanolamine [18:1] (DOPE) and 1,2-dioleoyl-sn-glycero-3-phosphocholine 
[18:1] (DOPC) at a molar ratio of 3: 3: 10 were dissolved in 1 ml of chloroform. This 
solution was mixed with the phospholipid (PL) mixture in AFT: total lipid molar ratios 
of (0.25:1, 0.5:1, 0.75:1, 1:1, 1.25:1, and 1.5:1). Chloroformic solutions were evaporated 
using a Buchi® rotary evaporator at a temperature just above the phase transition 
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temperature(Tm) (55 oC) to form a thin dried film. The lipid film was hydrated with buffer 
(pH 7.4).  The mixture was incubated for 10 min in a water bath at a temperature above 
the Tm at 55 °C with intermittent vortexing to produce multilamellar vesicular liposomes 
and to ensure that all the lipids were dispersed in the buffer.  For preparation of small 
multilamellar liposomes, liposomes were sonicated (for 30min) using an Ultrasonic 
cleaner® bath sonicator at + 55oC. Unloaded liposome (free) were prepared (without 
AFT) as control. 
2.3.2.2. Size Reduction of Liposomes by extrusion  
The resulting liposomal dispersions were filter-extruded through a polycarbonate 
TrackEtch Nuclepore membrane (Whatman, UK). Up to 1 mL of liposomes formulations 
were passed back-and-forth five times through double stacked membranes with 200-nm 
polycarbonate membrane filters. The extrusion was done by hand with a syringe extruder 
(Liposo-Fast™ Avestin Inc., Ottawa, Canada) (Figure 2- 2). To allow the formation of 
smaller vesicles, this was followed by extrusions through 100-nm polycarbonate 
membrane filters and the procedure was repeated 21 times. During all the extrusions, the 
temperature was maintained at least 10 °C above the glass transition temperature of the 
DSPC (55°C). The resultant products were stored in the fridge at 4°C overnight prior to 
characterization.    
2.3.2.2. Preparation of targeting AFT-loaded liposome nanoparticles       
Cationic and pH-sensitive phospholipids were produced using the same thin film 
hydration method except 3 of the 10 parts of DOPC in the total liposomes composition 
were replaced by either 1,2-dioleoy-3-trimethylammonium-propane chloride salt 
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(DOTAP) or cholesteryl hemisuccinate (CHEMS) for the development of cationic and 
pH sensitive liposomes, respectively as shown in Table 2- 1.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2- 1: Thin film hydration method (I & II phospholipid 
solutions and III is drug). 
B 
Figure 2- 2: Mini-Extruder. The polycarbonate membrane and filter supports are 
placed between two Teflon internal membrane supports. 1.0 ml Hamilton syringes are 
connected to the extruder outer casting. Photo of liposome dispersions: Left (A): crude 
liposomes Right (B): after extrusion through 0.1 µm membrane.   
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Table 2- 1: Compositions of different types of liposomes. 
  
 
 2.3.3. Physicochemical characterization of liposomal 
nanoparticles 
2.3.3.1. Determination of particle size, polydispersity and Zeta 
Potential 
The mean vesicle size, size distribution and zeta potential were characterized by dynamic 
light scattering (DLS) at 25oC with a fixed angle of 137° using a Zetasizer Nano ZS 
(Malvern Instruments Ltd., UK). The liposomes were appropriately diluted with purified 
and filtered water (0.2 µm pore size) prior to the measurements. The mean vesicle 
diameters were the averages of five measurements. All measurements were done in 
triplicate. 
Phospholipids Amount required (µmol/mL) 
NL PSL CL 
DSPC 3 3 3 
DOPC 10 7 7 
DOPE 3 3 3 
CHEMS - 3 - 
DOTAP - - 3 
NL: Non-targeting liposomes; PSL: pH-sensitive liposomes; CL: Cationic liposomes; DSPC: 1,2-
distearoyl-sn-glycero-3-phosphocholine [18:0]; DOPC: 1,2-dioleoyl-sn-glycero-3-
phosphocholine [18:1]; DOPE:1,2-dioleoyl-sn-glycero-3-phosphoethanolamine [18:1]; CHEMS: 
Cholesteryl hemisuccinate; DOTAP:1,2-dioleoy-3-trimethylammonium-propane Chloride salt 
(DOTAP) 
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2.3.3.2. Transmission electron microscopy 
The liposomal formulations were examined by transmission electron microscope (TEM) 
using a JEM-2100 electron microscope (Jeol, Tokyo, Japan). Briefly, a drop of liposomal 
formulation was applied to a copper coated carbon grid, and the excess was removed 
using filter paper, and then examined under the electron microscope. 
2.3.3.3. Determination of Encapsulation Efficiency  
Due to the poor solubility of AFT, the free AFT occurred in two forms in the external 
phase of the liposomal dispersion; free undissolved and free dissolved AFT. The free 
undissolved AFT was separated from the liposomes using light centrifugation. 
Meanwhile, the supernatant (encapsulated and free dissolved AFT) were filled into 
centrifuge tubes and ultra-centrifuged (Sorvall™ WX Ultra80 Floor Ultracentrifuge, T-
890 Fixed Angle Rotor, Thermo Electron Corporation) at 40000 rpm at 4 ◦C for 30 min. 
The clear supernatant which contained the free dissolved AFT was collected. The total 
AFT is the sum of both encapsulated and free AFT. The concentration of AFT within the 
liposome was determined after dissolving and disrupting the liposomal dispersion in 
methanol and triton x-100 using a vortex mixer, followed by centrifugation for 15 min. 
The clear supernatant which contained the AFT was then transferred to a new tube and 
kept at 4 ◦C until analysis.  The drug encapsulation efficiency (EE%) was calculated by 
using the following formula:  
 
𝐸𝐸 % =  ୅୊୘೟೚೟ೌ೗ – ஺ி்೑ೝ೐೐ 
୅୊୘೟೚೟ೌ೗
× 100                       Eq. 2.1 
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 2.3.4. HPLC Assay for Afatinib 
A simple, rapid and sensitive analytical method was developed and validated for AFT 
quantification. The developed method was characterized by the ease of sample 
preparation and the small sample volume required and validated for linearity, precision 
and accuracy.  
2.3.4.1 HPLC method 
A stock solution of AFT was prepared in methanol at a concentration of 1 mg/mL and 
stored in 4.0 mL amber glass vials at -20°C. Serial dilutions in mobile phase were 
performed in the range of 0.01 to 25 µg/ml to produce a standard calibration curve using 
HPLC analysis. A Waters Breeze2TM HPLC system (Waters Corporation, Milford, 
U.S.A) was equipped with an automated sampling system (WatersTM 2695 Plus 
Autosampler, USA) at 4°C and a photodiode array detector (WatersTM 2998, USA), 
“Breeze2 (WaterTM)” software and a reversed-phase C18 column (WaterTM, 3 x 150 
mm, 3.5 µm particle size) coupled with a C18 guard cartridge (4×2.0 mm) and maintained 
at 50°C. The mobile phase consisted of A: 0.1% triethanolamine and 1% acetonitrile in 
HPLC water (pH= 6), and B: acetonitrile and 10% methanol at a flow rate of 1 mL/min. 
The injection volume of each AFT sample was 10 μl and detected by the UV detector at 
253 nm. All the operations were carried out at room temperature. A daily standard 
calibration curve (n=3) ranging from 0.01 to 25 µg/ml was prepared to determine the 
unknown AFT concentrations for entrapment efficiency and drug release.   
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2.3.4.2. Assessment of Linearity, Accuracy and Precision 
Validation of the HPLC method was conducted according to the International Conference 
on Harmonization (ICH) guidelines [184] considering: linearity, accuracy, precision, 
specificity, limit of detection (LOD), limit of quantification (LOQ) and robustness. Six 
standard calibration lines were prepared at different times during 3 months to evaluate 
the linearity, precision, accuracy, and stability of the method.  
Linearity was assessed by calculating a regression line by plotting the peak area of AFT 
vs. the AFT concentration ranging from 0.01 to 25 µg/ml.  
The accuracy was determined via the analysis of multiple replicates (n = 6) of AFT 
concentration. The accuracy of the method was expressed in term of bias. 
The precision of a quantitative method was determined by repeatability as intra-day 
precision by an analysis of three replicates of AFT concentrations over the same day. 
Inter-day precision was determined by the analysis of three replicates of various AFT 
concentrations over three different days. The results were expressed as the relative 
standard deviation (RSD%).  
Low, medium, and high concentration quality control (QC) samples at concentrations of 
(100, 1,000 and 10,000 ng/ml AFT, respectively) were analyzed, on three distinct 
occasions within at least 3 months, as described above.  
The LOD and LOQ were determined from the calibration curve obtained using six 
replicates that were closest to the LOQ. The following equations were used: 
LOD = 3.3 σ/S      Eq. 2.2 
LOQ = 10 σ/S      Eq. 2.3 
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LOD and LOQ were determined based upon the slope (S) of the calibration curve and 
least standard deviation obtained from the response (σ). It has a low limit of quantitation 
(10 ng/ml) with satisfactory specificity, no matrix interference was observed.  These 
findings demonstrated that the assay has good selectivity.   
2.3.5. In vitro Drug release  
The in vitro release of AFT from NL, CL, and PSL (optimized formulations) was 
evaluated using a Franz diffusion cell system (FDC-6, LOGAN, Instruments Corporation, 
USA). The experiments were conducted in PBS buffer (pH 7.4 and 5.5) with 0.2% Tween 
80 to maintain sink condition. The cellophane dialysis membranes (molecular weight cut 
off: 12-14 KDa) were soaked before use in distilled water at room temperature for 12 h 
prior to use to ensure wetting. An aliquot of 100 μL liposome suspension was added into 
donor chambers, ensuring there were no air bubbles under the membrane. The receptor 
compartment consisted of PBS (pH 7.4) and pH 5.5 for PSL at 37 °C and stirred at 150 
rpm. Samples of 500 μL were withdrawn at various time intervals up to 24 h, and replaced 
immediately with an equal volume of fresh PBS at 37 °C. The amount of AFT in each 
sample was analyzed by HPLC. The experiments were performed in triplicate.  
2.3.5.1. Kinetic Modelling  
The in vitro AFT release data were fitted to various kinetic equations, including zero 
order, first order, Higuchi’s model and Korsmeyer Peppas plot and R2.  Then, n values 
(diffusion exponent) were calculated for each linear curve obtained by the regression 
analysis of each kinetic equation [185]. 
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2.3.6. Stability testing 
Liposomal formulations were stored in glass vials at 4±1 °C and 25°C ± 2°C over a period 
of one month. The stability was evaluated by measuring the average particle size, zeta 
potential and PDI and AFT content after storage for one month. The physicochemical 
stability of the freshly prepared formulation (at day 1) was used as control and AFT 
content (at day 1) was normalized to 100%. 
2.3.7. Data and statistical analysis 
Quantitative data were expressed as the mean ± SD of at least three replicates. The 
Student’s t-test and one-way analysis of variance (ANOVA) using IBMSPSS Statistics 
21 was used to assess multiple comparisons between different methods and times. The 
level of confidence was set as 95%.  
 
2.4. Results  
2.4.1. Liposome size, polydispersibility index, and zeta 
potential determination 
The obtained liposomes were characterized in terms of mean particle size, PDI and zeta 
potential values using DLS and electrophoretic light scattering. The particle size of the 
liposomes ranged from 42 to 57 nm and values of PDI were less than 0.2, which indicate 
a narrow size distribution and no aggregation. The zeta potential values increased with 
increasing AFT: lipid ratios, until the ratio was 0.5:1 (Figure 2- 3). The AFT-containing 
liposomes exhibited more positive zeta potential than liposomes without AFT, which 
suggests that the addition of AFT increased the zeta potential of liposomes. In case of the 
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NL, the positive zeta potential was low and after the incorporation of AFT, increased by 
approximately two-fold until a ratio of 0.5:1 of AFT: lipid. CL were more positive, with 
zeta potential ranging from 38.9 mV for the blank to 48.4 mV for the ratio of 0.5:1. 
However, PSL were negatively charged due to CHEMS and zeta potential decreased with 
increasing the drug to lipid ratios (Figure 2- 3).  
 
 
 
 
 
 
 
2.4.2. Transmission electron microscopy 
Transmission electron microscopy images of PSL are presented in (Figure 2- 4) showing 
that PSL were uniform, homogenous and spherical shape liposomes with smooth surface 
and had a multilamellar structure that was clearly visible inside PSL. The liposomes 
observed under TEM were ˂50 nm which was in good agreement with the dynamic light 
scattering measurements. 
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Figure 2- 3: Zeta potentials of NL (Non-targeting liposomes), CL (Cationic 
liposomes), and PSL (pH-sensitive liposomes) at different lipid to AFT ratios. 
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2.4.3. Chromatographic Analysis of Afatinib 
The maximum UV absorbance for AFT was determined to be 206 and 253 nm which is 
in contrast to values reported in the literature of 252, 258 or 268 nm [186-188]. The 
detection wavelength of 253 nm was used for a better quantification of AFT in the HPLC 
in this study due to the higher peak area.  As shown in Figure 2- 5, the average retention 
time was 2.4 min, with no interfering peaks in either chromatogram A (the blank) and 
chromatograms B and C (AFT) indicating the specificity of the HPLC assay method. 
During the in vitro studies, there was no interfering peaks from the NP ingredients co-
eluted with the AFT peak, which further confirmed the specificity of the method.  
Figure 2- 4: TEM micrographs of the pH sensitive liposome at AFT:lipid ratio of 
0.5:1 (PSL), at A) 25,000×, B) 40,000× C) 120,000 x, and D) 150,000 x 
magniﬁcations power. 
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2.4.3.1 Method validation 
A calibration curve of the peak area of AFT vs. concentration in the range of 0.01 to 25 
µg/ml was produced. The regression equation of the line was y = 355.74x + 1.6229) with 
a correlation coefficient (r2) of 0.9999 (Figure 2- 6).  
The analytical method was validated in terms of linearity, precision, and accuracy. 
Linearity was assessed using a calibration curve to investigate the ability of the method 
to get a proportional response to the different concentrations. Based on concentrations 
from 0.01 to 25 µg/mL, the linearity was evaluated in triplicate, and a calibration curve 
constructed.  
The LOD was determined to be 5 ng/ml and the LOQ was 10 ng/ml, with the 
corresponding CV values of 1.8 and 0.926 %, respectively (Table 2- 2). For precision and 
accuracy of sample analysis, AFT standard solutions of three replicates were prepared in 
triplicate and analyzed on the same day (repeatability) or in three different days 
(intermediate precision). Table 2- 3 shows that the precision did not exceed the required 
RSD value with a maximum value < 1.98 %. Analysis of variance of the data indicated 
no significant difference (p =0.401) in the slopes, intra- and inter-day of the calibration 
curves. The results confirmed the reproducibility of the assay with an accuracy of >99.9 
%.  The method was found to be robust, since small variations in the method conditions 
had a negligible effect on the chromatographic behavior of the AFT. The results also 
indicated that changing the HPLC system or the C18 column had no effect on the analysis 
of AFT. Even a small change in the mobile phase composition did not significantly 
change the peak area of the drug used for this method.  
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A
B C 
Figure 2- 5: HPLC chromatograms of the mobile phase (chromatogram A), and 
HPLC chromatograms of the mobile phase containing (B) 10 ng/ml and (C) 50 
ng/ml afatinib. 
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Figure 2- 6: Standard calibration curve of afatinib solution in methanol at λ 253 nm 
(n = 6). 
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Table 2- 2: Precision of the developed method for analysis of afatinib. 
 
 
 
Table 2- 3: Inter day and Intraday accuracy determination of afatinib (n = 6). 
Nominal   
(µg/mL) 
Concentrations 
Mean ± SD CV% 
0.01 0.01 ± 6.09 0.9266 
0.05 0.05 ± 6.40 0.8051 
0.1 0.1 ± 5.71 1.7143 
0.25 0.25 ± 1.76 0.7076 
0.5 0.5 ± 5.70 1.1404 
1 1 ± 1.77 0.1763 
2 2 ± 4.03 2.3016 
5 5 ± 5.65 1.0731 
10 10 ± 3.76 1.3577 
20 20 ± 3.83 0.1992 
25 25 ± 2.55 0.1102 
   SD: standard deviation; CV: Coefficient of variation percentage 
 
 
Concentration 
(µg/ml) Mean ± SD
a Precision RSDb (%) 
Accuracy 
 (%) 
Inter day    
0.1 99.98 ± 1.98 1.98 99.9 
1 1000.72 ± 0.49 0.05 102 
10 10000 ± 113.26 1.13 100.1 
Intra-day    
0.1 100 ± 1.06 1.07 99.86 
1 1000 ± 0.29 0.03 100.5 
10 10000 ± 60.08 0.6008 100.2 
a   Standard deviation of the mean 
b   Relative standard deviation 
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2.4.4. Encapsulation efficiency of AFT in liposomes 
The effect of the lipid to AFT ratio on the encapsulation of AFT is indicated in Figure 2- 
7. As the AFT: lipid ratio increased, the EE% was increased to a certain extent and then 
decreased in all tested formulations. The highest values of encapsulated AFT were with 
AFT:lipid ratio of 0.5:1 where the EE% values were 43, 50, and 52 % for NL, PSL, and 
CL respectively. As expected, the amount of AFT in the liposomes increased with 
increasing AFT ratio. After reaching the maximum encapsulated amount of AFT in 
liposomes, EE values decreased with additional AFT. However, the amount of 
undissolved drug increased (P< 0.05) significantly, thereby notably decreasing the EE% 
values.  As the amount of undissolved drug increased and were present as free crystals 
that were visible in TEM-images (Figure 2- 8). According to the obtained results, AFT: 
lipid ratio 0.5:1 was selected for further studies due to the high EE% in all tested 
liposomes. In contrast, PSL at a lipid to drug ratio of 1:1 showed the lowest EE%.   
////// 
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Figure 2- 7: Encapsulation efficiency % of NL (non-targeting liposome), PSL (pH 
sensitive liposome) and CL (cationic liposome) with different drug: lipid ratios. 
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2.4.5.   In vitro Release of AFT 
To evaluate the in vitro drug release of AFT from CL and PSL compared to NL, NPs 
were incubated in PBS solutions (pH 7.4) at 37oC (Figure 2- 9). Moreover, to determine 
the pH sensitivity of PSL, AFT release behavior at pH 5.5 was also investigated, and pH 
5.5 was selected to mimic the tumor pH (Figure 2- 9) as weakly acidic environments are 
present in the endosomal and lysosomal compartments of tumor cells [189]. The AFT 
release rate was relatively slow in neutral pH 7.4, only reaching 59.5%, 35.4% and 28.6 
% for CL, NL, and PSL, respectively within 24 h. These data revealed that the liposomes 
exhibited significantly sustained release profiles and AFT was successfully loaded into 
the liposomes. However, the cumulative release of AFT in PSL at pH 5.5 reached 101 % 
in 4 h, presenting a burst release phenomenon.  
 
Crystals of drug 
Figure 2- 8: Free afatinib crystals present in the suspension of PSL (pH 
sensitive liposomes) formulated at a AFT: Lipid ratio of 1.5:1. 
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To fit the release kinetics of AFT from liposomes at pH 5.5 and 7.4, different kinetic 
models viz. Peppas, Higuchi, zero Order and first order were exploited to predict the dug 
release profile. The data supported the Korsmeyer-Peppas model at pH 7.4 as it presented 
the highest value of r2. Moreover, the values of n were 0.460, 0.681, 0.431 and 0.599 for 
CL, NL, PSL and PSL (pH 5.5), respectively, indicating a non-Fickian diffusion kinetics 
(0.5 ˂ n ˂ 1). PSL (n=0.431) followed Fickian diffusion due to slow release at neutral 
condition. Subsequently, it was concluded that the drug release mechanism was mainly 
due to the combination of diffusion and erosion of the liposomes containing AFT (Table 
2- 4). 
 
 
0
20
40
60
80
100
120
0 5 10 15 20 25
Cu
m
m
ul
at
ive
 re
lea
se
 %
Time (hr)
CL
PSL
NL
PSL
(pH 5.5)
Figure 2- 9: In vitro release profiles of NL (nontargeting liposome), PSL (pH 
sensitive liposome) and CL (cationic liposome) in phosphate-buffered saline 
containing 0.2% Tween 80 at pH 7.4 and pH 5.5. Values are presented as the mean 
± SD. 
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Table 2- 4: Modeling of Afatinib release kinetic from different liposomal formulations. 
 
2.4.6. Stability of AFT liposomal dispersions 
The short-term stability of selected liposomes, in liquid form, prepared from a AFT: lipid 
ratio of 0.5:1: was investigated for up to 30 days at 4 ± 1oC and 25 ± 2oC. There was no 
significant change in the particle size, PDI, zeta potential or EE% of the liposomes 
compared to the initial preparation over the course of the stability study at 4°C (p > 0.05). 
However, at 25 oC, the particle size of the liposomes after storage for 30 days increased 
from 47.5±2.3 to 75±3.3 nm, 53.8±2.6 to 84±15.9 nm and 55.3±1.2 to 79.5±2.5 for CL, 
PSL and NL respectively. However, the liposomes were still smaller than 100 nm and 
there was no appreciable change in PDI. The zeta potential at 4°C and 25oC for 30 days 
 NL CL PSL PSL 
At pH = 7.4 At pH = 5.5 
Zero- 
Order 
r2  0.928 0.691 0.754 0.647 
ko (h-1) 1.900 4.017 1.776 6.606 
First- 
Order 
r2 0.731 0.559 0.634 0.486 
k1 (h-1) 0.025 0.106 0.022 0.477 
Higuchi r2 0.988 0.871 0.912 0.835 
k1 (h-½) 7.676 16.32 7.145 28.05 
Korsmeye
r-Peppas 
r2 0.994 0.940 0.971 0.889 
kKP (h-n) 0.259 0.247 0.280 0.604 
“n” value 0.681 0.460 0.431 0.559 
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was not significantly different (p =0.141) compared to initial formulation. The EE of AFT 
after storage at 4°C and 25°C for 30 days was slightly decreased, but was still higher than 
90% and 80%, respectively, of the initial formulations (Figure 2- 10). Therefore, 
liposomes formulations were stored at 4oC at all the time.   
  
 
2.5. Discussion 
Liposomes have been reported as potential drug carriers to target cancer cells. Liposomes 
less than 100 nm are able to escape the tumor vasculature and accumulate in the cells by 
passive targeting [190]. Moreover, targeted liposomes were designed depending on the 
type of phospholipids used. In addition, AFT is a potent antitumor drug used in clinical 
oncology against a lung tumor. However, AFT had low specificity, systemic toxicity and 
indiscriminating of the tumor and healthy tissues [191]. So AFT loaded liposomes NPs 
were developed for successful cancer therapy to decrease dose-limiting toxicity. In this 
Figure 2- 10: Drug content of afatinb from NL (nontargeting liposome), PSL (pH 
sensitive liposome) and CL (cationic liposome) at Afatinib: Lipid (0.5:1), following 
storage for one month at 4 and 25°C, p = 0.141. 
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study, two different strategies for AFT loaded liposomes for tumor targeting were 
selected. Cationic and pH-sensitive phospholipids were used to produce AFT cationic 
liposome (CL) and AFT pH-sensitive liposome (PSL) to target tumor cells, in addition to 
the conventional (nontargeting) liposome (NL). The main difference between these two 
liposomes is the composition of phospholipid used. In general, three lipid components: 
DSPC, DOPC, and DOPE were used. The rationale for the selection of DSPC was its 
stability against chemical degradation due to being a saturated lipid, which reduces the 
drug leakage from liposomes on storage and in vivo transit. To increase the fluidity of the 
liposomal membrane, DOPC was selected due to its high fluidity at room temperature 
(transition temperature (Tm)= −20°C). While, the Tm of DSPC is +55 °C, which remains 
in the gel phase [192]. Moreover, DOPE was added to provide fusogenic characters to 
the liposomes, due to the formation of an inverted hexagonal phase upon destabilization 
of membranes at a mildly acidic pH [84]. These lipids, with various chain lengths and 
degrees of saturation, can be used to fine-tune the membrane dynamics and phase 
properties [84]. The main composition of CL is DOTAP, which is a cationic phospholipid. 
Whereas PSL is composed of the pH-sensitive phospholipid (CHEMS). 
The film hydration method has been used to actively entrap AFT into liposomes with 
relatively high efficiencies and small vesicle size (<100 nm) [193]. The polydispersity 
index values of the obtained liposomes are ˂ 0.2 indicating narrow size distribution. These 
findings are in agreement with Mayer et al 1986 who showed that similar procedures can 
be employed for the production of homogeneously sized liposomes by utilizing filters 
with pore sizes ranging from 30 to 400 nm [194]. These small sized liposomes have the 
potential to penetrate tumor cell membranes and be taken up by the cells allowing 
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efficient drug accumulation at the target site. The TEM of PSL revealed uniform, 
homogenous and spherical-shaped liposomes with a smooth surface. The higher zeta 
potential of the obtained liposomes provoked the potential stability of a liposome. 
Depending on the lipid composition, liposomes and lipid nanoparticles may carry a 
negative, neutral, or positive net charge. Absence of surface charge (neutral liposomes) 
increases the aggregation of liposomes, reducing their physical stability. Also, neutral 
liposomes do not interact sufficiently with cells, and this leads to drug release from the 
liposomes in the extracellular space [165, 195]. Instead, charged liposomes have several 
advantages compared with neutral liposomes. Therefore, cationic and pH-sensitive 
phospholipids were selected for tumor targeting  
 The zeta potential of the liposomes was influenced by the lipid composition. The cationic 
lipids DOTAP increased the zeta potential of the liposomes, while CHEMS had a 
negative effect on the zeta potential.  
Kraft et al found that liposomes having a net positive or negative charge  accumulated to 
a greater extent in the lung, compared to uncharged/neutral liposomes [196]. Patil et al 
investigated the effect of zeta potential of cerium oxide nanoparticles on cellular uptake 
in adenocarcinoma lung cells (A549) showing preferential cellular uptake for the 
negatively charged nanoparticles [165]. Thus, the attachment of liposomes to cell 
membrane appears to be most affected by the surface charge of the liposomes.  
Furthermore, to obtain the liposomes with the highest EE%, the best ratio of drug to 
phospholipid was determined for further studies. Accordingly, the highest EE% of AFT 
was 43.20%, 50.20%, and 52.01% for NL, PSL, CL, respectively at the 0.5:1 ratio of 
AFT: lipid and the reproducibility was good. Positively charged liposomes (CL) exhibited 
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the highest drug content, due to the inclusion of DOTAP in the liposomes, which 
decreases the rigidity of the liposomes increasing loading capacity. However, increasing 
the molar ratio of AFT: lipid above 0.5:1, in all formulations, produced a noticeable 
decline in EE%, since there was not enough lipid to entrap the drug. On the other side, 
the amount of free drug increased (P ˂0.05) significantly with increasing the molar ratio 
of AFT: lipid, thereby decreasing the percent encapsulated drug dramatically. Afatinib is 
a lipophilic substance, which is easily compatible with the phospholipids used in the 
preparation of liposomes and forms a part of the bilayer. The incorporation of AFT into 
liposomes is limited by the availability of encapsulating material as with the three types 
of liposome prepared. The high EE% also indicated that the lipid bilayer was able to 
significantly solubilize the hydrophobic drug (AFT), enabling it to be transported through 
the inner vesicle, which would be an effective solution for the low oral bioavailability of 
AFT. In this line, Nallamothu et al., found that total liposomal concentration levels 
increased with increasing lipid concentration in the formulation. As the drug: lipid ratio 
increased from 1:10 to 2:10, total drug in the liposome formulation increased. When the 
drug: lipid ratio was further increased to 4:10, the total drug in liposome formulation did 
not increase, but the amount of free drug increased significantly, thereby decreasing the 
percent of entrapped drug. Therefore, at higher drug: lipid ratios there are not enough 
lipids to entrap the drug, so most of the drug is in free, or un-entrapped, form [197].  
Thus, the best liposomes were subjected to a stability study, where they exhibited better 
stability at 4°C or at 25°C after storage for 1 month. In terms of EE%, particle size and 
zeta potential, CL showed the highest stability.In vitro drug release data revealed that 
PSL and NL demonstrated better sustained release profiles than CL due to the presence 
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of DSPC (Tm), which led to a decrease in leakage of AFT in the circulation or extracellular 
environment. But in case of CL, AFT exhibited a high release rate compared with the 
other liposomes, at pH 7.4. This is due to the complete protonation of DOTAP at pH 7.4 
[198]. By contrast, the AFT release was increased significantly when the pH decreased 
from 7.4 to 5.5 in the case of PSL and showed reasonably good pH-responsiveness, 
reaching 100% after 4 h. In a physiological environment (pH 7.4), the encapsulated AFT 
was released at a constant rate. These results indicated that the AFT was well protected 
inside the liposome bilayers at physiological pH but in acidic condition (pH 5.5) such as 
a cancer tumor environment, the AFT release would be hastened.  Therefore, the release 
of the PSL containing AFT was controlled by the environmental pH. The PSL underwent 
destabilization at pH 5.5 and acquired fusogenic properties, thus tending to rupture and 
quickly release the AFT. This is in line with the results obtained by Düzgünes et al [199] 
who proved that under acidic conditions, CHEMS becomes partially protonated, 
consequently losing its negative charge and, therefore, its ability to stabilize the bilayer 
structure. This results in the destabilization and/or fusion of the liposomes. These 
liposomes showed that liposomes composed of CHEMS stabilized the entrapment of 
calcein at pH 7.4 and undergo destabilization and irreversible aggregation under acidic 
pH [200]. Also, the fusogenic performance of PSL is due to the presence of DOPE in its 
lipid layer, which forms a hexagonal structure instead of bilayer structure, when dispersed 
in aqueous media. Doxorubicin was encapsulated in pH-sensitive liposomes, which 
contained DOPE and CHEMS, leading to high intracellular drug release rates within 
acidic compartment resulting in further increments in the therapeutic efficacy of targeted 
anticancer drug containing liposome against B lymphoma [201].  
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It was reported that the release of the drug from liposomes could be described by  three 
different mechanisms: diffusion, erosion and diffusion-erosion [202].  It was found that 
the release profiles were supported by the Korsmeyer-Peppas model at pH 7.4, which is 
presented the highest value of r2. Moreover, the values of n, the release exponent 
indicating the drug release mechanism, were 0.460, 0.681, 0.431 and 0.599 for CL, NL, 
PSL and PSL (pH 5.5), respectively, indicated a non-Fickian diffusion kinetics (0.5 ˂ n 
˂ 1). While PSL (n=0.431) exposed Fickian diffusion due to slow release at neutral 
condition [202]. Subsequently, it is concluded that the drug release mechanism was 
mainly owing to the combination of diffusion and erosion of the liposomes containing 
AFT (Table 2- 4).  
2.6. Conclusion 
In this study, a sensitive and selective HPLC method was developed for the quantification 
of AFT in formulations.  Afatinib was successfully incorporated in a variety of different 
liposomes with different ratios of lipid to AFT, NL, CL and PSL, using a film hydration 
method. The obtained liposomes were small vesicles less than 100 nm with a low PDI 
(<0.2) and accepted zeta potential. The highest EE% of AFT obtained was 43%, 50%, 
and 52% for NL, PSL, CL, respectively at the 0.5:1 ratio of AFT to lipid. The in vitro 
release study confirmed that PSL, CL and NL had sustained release profiles in pH 7.4. 
However, in acidic pH solutions, PSL exhibited fast release. The stability study, 
conducted at 4°C and 25°C for 1 month, showed that the characteristics of liposomes in 
liquid form did not change significantly over this period. This study suggests that NL, 
PSL, and CL containing AFT should be further investigated for cytotoxicity to NSCLC 
lung cell line.   
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Chapter 3 
 
In vitro Cytotoxicity and Molecular 
Studies of Afatinib- Liposomal 
Formulations  
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3.1. Introduction 
Cell culture assays have been used widely in different fields such as cancer, and are 
critical steps in determining the efficacy, pharmacodynamics, and mechanism of action 
of novel anti-cancer drugs. [203]. Also, they are favoured as preliminary data to predict 
the performance of drug-loaded NPs systems  before moving onto in vivo studies [48]. 
In order to improve the therapeutic efficacy of AFT, AFT-loaded liposomes (NL, CL, and 
PSL) system were developed as described in chapter 2. Subsequently, the potential 
toxicity of these vesicles needed to be addressed. Human NSCLC cell lines (H-1975, 
H1650, and   HCC-827) were utilised in the cytotoxicity studies as relevant pulmonary in 
vitro models for liposome DDS (Table 3- 1). The H1975 cell line has L858R/T790M 
double mutations; and H1650, and HCC827 cells both have  an EGFR exon 19 deletion 
which are the most common EGFR mutations found in patients with NSCLC [204].  
Four chemotherapeutic regimens: cisplatin and gemcitabine, cisplatin and docetaxel, 
carboplatin and paclitaxel, and cisplatin and paclitaxel are used for treatment of NSCLC, 
affording an average overall survival of 8–10 months [205]. More recently, the 
identification of lung tumours having mutations in EGFR has led to  attention on targeted 
treatments for EGFR tyrosine kinase inhibitors resulting in an overall survival of more 
than 2 years for patients with EGFR mutation-positive NSCLC [71].  Therefore, 
gemcitabine, carboplatin and paclitaxel were used to compare efficacies with AFT (Table 
3- 2). 
There are many methods that can be used to investigate cytotoxicity, which involve 
different aspects of cell function, for example cell viability and proliferation, cell 
morphology, and loss of membrane integrity. [125, 206-208].  WST-1 is a colorimetric 
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method which provides a tool for studying induction and inhibition of cell proliferation 
in any in vitro cell model [209]. The WST-1 assay is considered to be better than older 
cell viability assays as it does not have the additional solubilisation step as with 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) and can be measured after 
2 - 4 hrs incubation. WST-1 is a stable tetrazolium salt cleaved to a water-soluble orange-
coloured salt called formazan by mitochondrial dehydrogenases that are present at viable 
cell surfaces [210]. The amount of formazan dye formed is directly proportional to the 
number of metabolically active cells in the culture [211].  
 
Table 3- 1: Non small cell lung cancer lines used in this study. 
Cell line name Gender ATCC® No. Histology 
H-1975 Female CRL-5908™ Adenocarcinoma 
H-1650 Male CRL-5883™ 
Stage 3b, Adenocarcinoma; 
Bronchoalveolar Carcinoma 
HCC-827 Female CRL-2868™ Adenocarcinoma 
 
 
Clarifying the mechanism of cytotoxicity of NPs and controling the expression of 
cytotoxicity should facilitate the development of safe liposomal formulations [212]. 
Apoptosis has been shown to play a major role in multiple physiologic and pathologic 
processes, such as oncogenesis, and tumor progression [213]. Unlike necrotic cell death, 
apoptosis is characterized by cell shrinkage, chromatin condensation, DNA 
fragmentation, and finally disintegration into apoptotic bodies [214]. 
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To understand the unique response of cells to NP therapeutics, quantitative proteomic 
technology has been used to study the protein expression profiles of NSCLC cells during 
treatment with chemotherapeutics [215, 216]. With the development of advanced 
instruments and maturation in sample preparation approaches, variations in cellular 
protein abundance as well as phosphorylation events that occur under different treatment 
regimens can be detected and analysed. Therefore, identification of proteins that are 
differentially expressed as a result of exposure to drug treatments may provide novel 
biomarkers for drug targets with improved therapeutic action, and/or predict outcomes 
during cancer treatment [217-219]. A Synapt G2 HDMS quantitative proteomic approach 
has been utilized to evaluate cellular protein abundance changes upon AFT treatment.  
 
3.2. Aims 
In this study, the aim was to evaluate the efficacy of the novel AFT-loaded liposomal NPs 
formulations (NL, CL, and PSL) compared to AFT alone.   
The main objectives of study were to: 
a. Study AFT-loaded liposomal NPs cell toxicity in vitro using NSCLC cells. 
b. Use flow cytometry to investigate the inhibition of cell proliferation induced by 
AFT and AFT-loaded liposomal NPs in NSCLC cells. 
c. Use proteomic methods to identify differentially expressed proteins in different 
treated and control NSCLC cells. 
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3.3. Materials and methods 
3.3.1. Materials 
Lung cancer cell lines (Table 3- 1) were purchased from the American Type Culture 
Collection (ATCC), Manassas, USA. RPMI 1640 1x, 0.25% Trypsin-EDTA Solution, 
Ammonium bicarbonate, Iodoacetamide, and DL-Dithiothritol were purchased from 
GIBCO®, SIGMA-ALDRICH, Saint Louis, USA. WST-1 Cell Proliferation Assay Kit 
Reagent were purchased from Roche Diagnostics (Basel, Switzerland). Antibiotic-
Antimycotic (100X) and Fetal Bovine Serum (FBS) were purchased from GIBCO®, 
InvitrogenTM, Carlsbad, USA. Vybrant® Apoptosis Assay Kit were purchased from 
Molecular ProbesTM, Life TechnologiesTM, Eugene, Oregon, USA. Protein Assay Dye 
Reagent Concentrate were purchased from Bio-Rad Laboratories, California, 
USA.RapiGestTM SF Surfactant and Mass PREPTM Alcohol Dehydrogenase Digestion 
Standard were purchased from Waters Corporation, 34 Marple Street, Manchester, UK. 
25 and 75 cm2/tissue culture flasks with vented cap (IWAKI brand) 96-well flat bottom 
plates 24-well tissue culture plates were purchased from Fisher Scientific, UK. 
3.3.2 Methods 
3.3.2.1. Liposomes formulation synthesis and characterisation  
Afatinib loaded liposomes (NL, CL, and PSL) and free (unloaded) liposomes were 
formulated and characterised as described in section 2.3.2 and section 2.3.3 respectively. 
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3.3.2.2. Cell Culture   
Non small cell lung cancer cell line (Table 3- 1) cells were cultured in RPMI-1640 
medium supplemented with 10% FBS/1% Antibiotic/Antimycotic solution (complete 
medium) incubated at 37°C into 5% CO2 incubator. The medium was changed every four 
days and cells were passaged weekly using Trypsin. 
3.3.2.3. Cytotoxicity study 
3.3.2.3.1 Cell proliferation assay, WST-1  
The in vitro cytotoxicity of AFT compared to different chemotherapeutic agents 
(carboplatin, gemcitabine and paclitaxel) (Table 3- 2) was determined by WST-1 using 
NSCLC cells (H-1975 cells) and  . In brief, the cells were seeded into 96-well plates at a 
density of 1x104 cells per well and incubated overnight in complete culture medium. 
Afterwards, different concentrations of AFT (1, 5, 10, 20, 40 and 80 M) were added to 
each well and incubated for an additional 24 h. At the end of the treatment, 10 µl of cell 
proliferation reagent WST-1 kit was added and incubated for 4 h at 37oC. The intensity 
of the photometric metabolite (formazan) was measured at 450 nm using an xMark™ 
Microplate Absorbance Spectrophotometer (Bio-Rad Laboratories, Inc., Hercules, CA, 
USA). The results were expressed as the IC50, which was obtained graphically using 
SigmaPlot 10 (SYSTAT Software, Inc., San Diego CA, USA). 
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Table 3- 2: The selected drugs used to compare their cytotoxicity effects with afatinib. 
No. Name Manufacture 
1                 Carboplatin Actavis 
2 Gemcitabine Ebewe 
3                  Paclitaxel Actavis 
 
 
3.3.2.3.2. Cytotoxicity assessment by flow cytometry 
Cell death was assessed using the Vybrant® Apoptosis Assay kit and flow cytometry. 
This was performed at the Flow Cytometry Core Facility at Research Centre (KFSHRC, 
Riyadh, KSA).  The H-1975 cells were seeded in six-well plates at 7 x 104 cells per well 
and incubated overnight. Then, the cells were treated with pure free liposomes, as control, 
and AFT loaded PSL at concentrations of 0.5, 1, 3, 5 and 8 µM for 24 h after dilution 
with complete culture medium. After treatment, the cells were harvested by 
trypsinization, centrifuged, and re-suspended in PBS. The cells were stained with Alexa 
Fluor® 488 Annexin V/propidium iodide (PI) and analyzed using the flow cytometer. 
The percentage cell death was determined using FACS-CaliburTM apparatus and 
CellQuest Pro software (Becton-Dikinson Biosciences, Franklin Lakes. NJ, USA). The 
apoptosis in different cells; H-1975, HCC-827 and H-1650 was tested after application 
of AFT or AFT loaded liposomes (NL, CL and PSL at 0.25, 0.5, 0.75, 1 and 2 µM) and 
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using free liposomes as control. The percentage of cell death in the wells containing the 
free drug and PSL following a 48 and 72h incubation period was subsequently compared 
with the results of 24 h incubation at 0.25, 0.5, 0.75, 1 and 2 µM. 
 3.3.2.4. Proteins expression changes induced by afatinib  
3.3.2.4.1. Sample Preparation and Protein In-solution Tryptic Digestion  
The protein concentration of the whole cell lysates was determined using the Bradford 
assay.   An equal amount (100 µg) of complex protein mixtures was subjected to in-
solution tryptic digestion. Protein concentrations of 0.5 to 1 µg/µL were achieved at the 
end of in-solution tryptic digestion as previously described with minor modification [58]. 
Briefly, the proteins were denatured in 0.1% RapiGest SF (Waters, Manchester, UK) at 
80°C for 15 min, reduced in 10 mM DTT at 60°C for 30 min, centrifuged at 13,000 RPM 
for 10 seconds to bring together the condensation under the tube cap, allowed to cool to 
room temperature, and alkylated in 10 mM Iodoacetamide (IAA) for 40 min at room 
temperature in the dark. The samples were then trypsin-digested at an enzyme: protein 
ratio (w/w; 1 µg/µL trypsin concentration) of 1:25 overnight at 37°C with gentle shaking. 
The digestion/ RapiGest was quenched by incubation with 12 M HCl (4 µL/50 µL of 
sample) at 37°C for 15 min, followed by centrifugation at 13,000 RPM for 10 min. The 
samples were then diluted with aqueous 0.1% formic acid to allow for a load of 
approximately 3 µg on the analytical column using the Trizaic Nano tile. All samples 
were spiked with yeast alcohol dehydrogenase (ADH) as an internal standard at a final 
concentration of 200 fmol per injection to facilitate absolute quantitation as previously 
described (Figure 3- 1) [219].  
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3.3.2.4.2. Protein Identification by Synapt G2 Mass Spectrometry  
One-dimensional, (1-D) Nano Acquity liquid chromatography coupled with tandem mass 
spectrometry on a Synapt G2 HDMS (Waters, Manchester, UK) was used to generate 
expression proteomics data for H-1975 and H-1650 treated and control samples.  Prior to 
analysis, the instrument was optimized as previously described [218, 219]. Briefly, the 
detector was set using 2-ng/µL-leucine Enkephalin (556.277 Da). Mass/charge (m/z) 
calibration was achieved with a separate infusion of 500 fmol [Glu] 1-Fibrinopeptide B 
DTT: DL-Dithiothreitol, IAA: Iodoacetamide, Hcl: Hydrochloric acid 
Figure 3- 1: Overview of the protein determination experimental 
workflow. 
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(GluFib, 785.843 Da), on a Trizaic Infusion tile using the automated Mass Lynx 
IntelliStart. 
Other parameters were capillary voltage at 3.6 Kv, sample cone at 50 V, extraction cone 
of 5 V, source temperature at 85°C. All raw data acquisitions were performed on a Trizaic 
Nano source (Waters, Manchester, UK), using the positive ion mobility mode nano ESI 
at slow flow rate.  
A 3 µl sample containing approximately 3 µg of the digested protein was loaded onto the 
column, and samples were infused using the Acquity Sample Manager with a mobile 
phase consisting of A1 (99% water +1% acetonitrile + 0.1% formic acid) and B1 (100% 
acetonitrile + 0.1% formic acid, with a fast sample flow rate of 1 µl/min). Data-
independent acquisition/iron mobility separation experiments (MSEs) were performed, 
and data were acquired over an m/z range of 50 - 2000 Da, scan time of 1 sec, ramped 
transfer collision energy of 20 to 50 V, and total acquisition time of 115 min. All samples 
were run in triplicate and repeated in 2 different experiments to ensure reproducibility of 
results. The data were accessed via the Mass Lynx program (Version. 4.1, SCN833, 
Waters, Manchester, UK) using the resolution and positive-polarity modes. The data were 
background subtracted, smoothed, and de-isotoped at a medium threshold. Progenesis 
LC/MS QI for proteomics (QIfp was used for all automated data processing and database 
searches. The generated peptide masses were compared against the Uniprot human 
proteome database (www.unprot.org) using Progenesis QI for proteomics (Waters, UK, 
Nonlinear, UK) for protein identification and differential analysis. 
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3.3.2.4.3. Data Analysis and Informatics 
Progenesis QI (Nonlinear Dynamics, Newcastle, UK) software was used for data 
processing and search. The software generated normalized label-free relative 
quantification analyses and significantly differentially proteins were subjected to 
unsupervised principal component analyses (PCA) for all sample groups.  Multivariate 
data analysis Variance (ANOVA) at p≤ 0.05 was used to identify significant alterations 
in regulated proteins and in addition, the expression level of at least ≥ 1.5-fold change 
between paired of samples being compared. 
3.4. Results  
3.4.1. In vitro cell viability assay of afatinib and other cancer 
drugs  
As shown in Figure 3- 2, the results demonstrated that AFT and paclitaxel on H-1975 
cells had a dose-dependent effect on cytotoxicity. On the contrary even up to the highest 
doses of carboplatin and gemcitabine minor cytotoxicity against H-1975 cells was 
observed. The IC50 values for AFT and paclitaxel were 20 and 25 µM, respectively. By 
increasing the concentrations of AFT to 40 µM, H-1975 cells exhibited higher sensitivity 
than with paclitaxel. The cell viability dropped to 2% with 40 µM of AFT and 50% with 
paclitaxel. Upon further increasing the concentration of AFT up to 80 µM, an 
insignificant reduction on the cell viability was observed (Figure 3- 2). Thus, 
demonstrating that AFT has potent cytotoxic effect (IC50 value; 20 µM) compared to 
other drugs. 
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The cell toxicity of the optimum liposomes PSL, NL, and CL was also measured by a 
WST-1 assay on H-1975 cells. Unfortunately, the reduction of cell viability (H-1975 
cells) at any AFT concentrations was not recorded. This behavior confirmed that the 
WST-1 assay unable to detect any reduction in viable cell numbers.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In contrast, the cytotoxicity (dose-dependent) was detected by microscopic examination 
using 1-80 µM of PSL, NL, and CL.Accordingly, intracellular vacuoles and cell 
aggregates at concentrations from 1 to 5 µM appeared. Further increasing the 
concentrations from 10 to 80 µM, resulted in observation of indefinite aggregates of 
damaged and dying cells. The order of liposomes toxicity to H-1975 cell was PSL > NL 
Figure 3- 2: Cytotoxicity of afatinib, carboplatin, gemcitabine and paclitaxel on H-
1975 cells, as determined by a WST-1 assay. Cells were treated with varying 
concentrations of the drugs for 24 h. Results are from three independent experiments 
and are expressed as the mean ± SD. 
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> CL. Therefore, AFT-loaded PSL at concentrations less than 10 µM were used for the 
next study. 
3.4.2. Annexin-V apoptosis assay 
The quantities of apoptotic cells increased from 55 to 58.9 % after exposure to 0.5 to 1 
µM of PSL. However, increasing the concentration to 8 µM resulted in a reduction of the 
quantities of apoptotic cells from 30% at 3 µM to 9 % at 8 µM. Furthermore, a high cell 
viability of 87.5 % with unloaded liposomes was observed. When the concentration of 
PSL was increased from 3 to 8 µM, the proportions of necrotic cells increased as the 
number of apoptotic cells decreased. The proportion of necrotic cells increased from 3 to 
90% depending on the concentrations of PSL at 0.5 and 8 µM (a dose-dependent manner) 
(Figure 3- 3B).  
Consequently, AFT at a concentration of 2.0 μM was selected for further cytotoxicity 
studies using different lung cancer cell lines due to the high apoptotic activity.  
The cell viability of PSL after H-1975 cells were incubated for 24, 48 and 72 h, was also 
measured (Figure 3- 4). A signiﬁcant cytotoxic effect in H-1975 cell at a concentration 
of 2 μM of PSL was observed, with the total cell death proportion exceeding 78, 80 and 
84 % after 24, 48 and 72 h, respectively. The cytotoxic effect of the PSL formulation at 
a concentration of 2 μM was mainly due to induced apoptosis, with slight necrosis. For 
comparison, the cell viability of unloaded liposomes at 72 h was 90 %. These results 
revealed no significant difference in the cell death after 24, 48 and 72 h of exposure with 
H-1975 cells (p > 0.05). Therefore, 24 h of exposure was selected for further study.  
Unloaded liposomes showed insignificant cytotoxicity (apoptosis) after 24 and 48 h of 
exposure with considerable toxicity (necrosis) after 72 h of exposure. 
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Figure 3- 3: H-1975 lung cancer cells were either treated with free liposomes, as control, 
or challenged with Afatinib loaded liposomes (PSL) for 24 hr, and then the proportion of 
apoptosis and necrosis was analyzed by Annexin V/PI flow Cytometry. four groups of 
cells, viable cells that excluded both Annexin V and PI (Annexin V-/PI-), bottom left; early 
apoptotic cells that were only stained with Annexin V (Annexin V+/PI- ), bottom right; late 
apoptotic cells that were stained with both Annexin V and PI (Annexin V+/ P+), top right 
and necrotic cells that were only stained with PI (Annexin V-/PI+), top left. (A) Flow 
charts. (B) Histogram showing the percentage of induced apoptosis in H-1975cells. 
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For further cytotoxicity study of PSL, CL and NL using different lung cancer cell lines a 
period of 24 h was selected. The anticancer activity of these liposomes was analyzed 
using flow cytometric with three cell lines: H-1975, H-1650, and HCC-827 (Figure 3- 
5A, B & C). This study was conducted to detect the level of apoptosis induced after 
incubation with various concentrations of 0.25, 0.5, 0.75, 1, and 2 µM of each liposome 
formulation for 24 h using dimethyl sulfoxide and unloaded liposomes as the controls. 
The incubation of the cells with unloaded liposomes did not induce notable cytotoxicity. 
The viability of H-1975 cells decreased more significantly compared to H-1650 and 
HCC-827 cells (p<0.05).  
 
Figure 3- 4:  H-1975 cells were challenged with pH-sensitive liposomes (PSL) (0.25-2 
μM) for 24, 48 or 72 h, following which apoptosis was analyzed with Annexin V/PI-
flow cytometry. Each value represents the mean ± SD of three independent experiments 
performed in triplicate. 
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Figure 3- 5: Non-small cell lung cancer cells were either treated with free liposomes, as 
the control, or challenged with AFT or AFT-loaded liposomes (PSL, NL, and CL) for 
24 h, following which the proportion of apoptotic cells was analysed using Annexin 
V/PI-flow cytometry. Histogram shows the percentage of induced apoptosis in H-1975 
cells. Each point represents the mean ± SD of three independent experiments performed 
in duplicate. 
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PSL produced highest cytotoxic effect in the different lung cancer cell lines (H-1975 cells 
and H-1650) compared to NL and CL, when using concentrations 2 µM AFT (Figure 3- 
5). Overall, the results clearly revealed the superior anticancer activity of PSL. 
3.4.3. Differentially expressed proteins in H-1975 and H-1650 
A total of 812 proteins were identified across all the sample groups. Among these 
proteins, 385 were significantly differentially expressed with at least ≥2-fold change (p< 
0.05) between treated and control samples from the two cell lines (H-1975 and H-1650). 
The dataset of 385 differentially expressed proteins was subjected to Principal 
Component Analysis (PCA) and all samples were distinctively clustered into four 
separate groups (Figure 3- 6). The H-1650, treated (Rx) and control (green and orange 
respectively) being slightly separated and (not as widely separated as in H1975 pairs). 
Pair wise comparison of protein expression changes between H-1975 treated (Rx) versus 
control (Ctrl) was performed resulting in 186 significantly differentially expressed 
proteins (Figure 3- 7).  Similar analysis of pairs of H-1650 Rx versus Ctrl indicated only 
27 proteins differed significantly. Only 12 proteins overlapped between the two datasets 
of significant protein changes between H-1975 Rx/Ctrl and H-1650 Rx/Ctrl (Figure 3- 7). 
This 12-protein panel might be considered as having similar treatment relatedness 
between the two different cell lines. The 385 identified differentially expressed protein 
dataset was subjected to pathway analysis of network signaling in order to further 
understand the biological processes of some of the identified proteins.  Only a fraction of 
the proteins was represented in the ingenuity pathway analysis database (Ingenuity 
Systems, Inc., Redwood, CA, USA) and the analysis of some of these proteins was 
composed of multiple cancer- related networks. 
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 Figure 3- 8 showed the identified proteins that have been associated with NSCLC. The 
connections and the expression profiles of some of the identified proteins are as indicated. 
The majority of these molecules are located in the cytoplasm and few of them located in 
the plasma membrane and another in the nucleus. While many of them act as enzymes, 
others act in kinase translation and transduction regulation as detailed in Table 3- 3.  
 
 
 
 
Figure 3- 7: Comparative analysis of the proteins identified in the study. 
Figure 3- 6: Principal Component Analysis (PCA) plot of 385 differentially expressed 
proteins (ANOVA 0.05 and ≥ 2-fold change) between both H-1975 and H-1650, treated 
(Rx) and control (Ctrl) cells. Four distinct clusters were observed with samples with H-
1975-treated and control (blue and purple respectively). H-1650, treated (Rx) and control 
(green and orange respectively).  The letters in grey scale are the accession numbers of each 
of the proteins. The PCA plot was generated from Progenesis QI for proteomics (Progenesis 
QIfp version 2.0.5387) (Nonlinear Dynamics/Waters)]. 
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Figure 3- 8: Pathway analysis of network signalling of some of the 385 identified 
proteins as represented in one of the networks signalling in the ingenuity pathway 
analysis database.  The connections and the expression profiles of some of the identified 
proteins are as indicated. Pink colour is indicative of downregulation. A direct 
connection is by solid line and broken lines indicate an indirect interaction between 
different molecules. Network analysis was performed and figure and table partly 
generated in an ingenuity pathway analysis program (IPA v8.7)]. 
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Table 3- 3: A selection of the identified 385 differentially expressed proteins between H-1975 and H-1650 at treatment and at control 
that were implicated in Ingenine Pathway Analysis as shown in figure 3- 8. 
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1 Q16543 11 9 0.0087 3.8039 H1975-Ctrl H1975-Rx CDC37 Hsp90 co-chaperone Cdc37 Cytoplasm kinase 
2 Q01518 10 7 0.0185 3.0779 H1650-Rx H1975-Rx CAP1 Adenylyl cyclase-associated protein 1 Plasma  
Membrane 
other 
3 P63167 1 1 0.0264 66.242 H1650-Ctrl H1975-Ctrl DYNLL1 Dynein light chain 1, cytoplasmic Cytoplasm other 
4 Q15056 2 1 0.0200 7.7860 H1975-Ctrl H1975-Rx EIF4H Eukaryotic translation initiation factor 4H Cytoplasm translation 
 regulator 
5 P41250 11 8 0.0121 2.8167 H1650-Rx H1975-Rx GARS Glycine--tRNA ligase Cytoplasm enzyme 
6 Q99714 1 1 0.0067 169.19 H1650-Ctrl H1975-Rx HSD17B10 3-hydroxyacyl-CoA dehydrogenase type-2 Cytoplasm enzyme 
7 P00338 30 22 0.0001 3.0382 H1975-Ctrl H1975-Rx LDHA L-lactate dehydrogenase A chain Cytoplasm enzyme 
8 P27816 16 10 0.0057 3.1206 H1975-Ctrl H1975-Rx MAP4 Microtubule-associated protein 4 Cytoplasm enzyme 
9 P35749 36 17 0.0101 2.0138 H1975-Ctrl H1975-Rx MYH11 Myosin-11 Cytoplasm other 
10 P35579 101 72 0.0001 6.6865 H1975-Ctrl H1975-Rx MYH9 Myosin-9 Cytoplasm enzyme 
11 P60660 14 10 0.0008 4.2310 H1975-Ctrl H1975-Rx MYL6 Myosin light polypeptide 6 Cytoplasm other 
12 P15531 8 1 0.0001 3.2862 H1650-Ctrl H1975-Rx NME1 Nucleoside diphosphate kinase A Cytoplasm kinase 
13 P13797 12 6 0.0049 4.4763 H1650-Ctrl H1975-Rx PLS3 Plastin-3 Cytoplasm other 
14 P17980 6 5 0.0145 3.9959 H1975-Ctrl H1975-Rx PSMC3 26S protease regulatory subunit 6A Nucleus transcription 
 regulator 
15 P09493 14 3 0.0006 4.1765 H1650-Ctrl H1975-Rx TPM1 Tropomyosin alpha-1 chain Cytoplasm other 
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3.6. Discussion  
In general, it is essential to screen and confirm that antitumor drugs are potent and 
efficient for cancer therapy. Therefore, the potency of AFT was evaluated in 
comparison with selected drugs depending on their efficacies against lung cancer in 
an in vitro cell-based assay. Half-maximal inhibitory concentration (IC50) of these 
drugs was attained from an experimentally derived dose-response curve. In this study 
the cytotoxicity was evaluated with a WST-1 assay in H-1975 cells. The cells were 
incubated with AFT, paclitaxel, carboplatin and gemcitabine for 24 h. The WST-1 
assay showed that AFT was more effective as a cytotoxic agent compared with other 
drugs commonly used for lung cancer treatments (Figure 3- 2). These results are 
comparable to results of two randomized phase III trials, where AFT exhibited 
significant benefit in progression-free survival compared with standard chemotherapy 
regimens in NSCLC patients with EGFR mutations [6, 32]. Similarly, in LUX-Lung 
6, AFT was compared with cisplatin plus gemcitabine. Afatinib showed a more 
profound and durable effect  and an increased progression free survival of 11 versus 
5.6 months compared with standard first-line chemotherapy (cisplatin plus 
gemcitabine) for Asian patients with NSCLC tumours having EGFR mutations [6].  
Since, WST-1 is a colorimetric assay and, by definition the measurement of colour in 
a solution, whereas liposomes have a whitish colour. It was observed that the 
phospholipids used in the liposome preparation, interfered with the colour formation 
and give rise to an opaque milky solution during the reaction with WST-1 which led 
to unreliable reading results. But under a microscopic examination, it was clear that 
CL NPs have the highest level of interference in the assay (data not presented) due to 
the cationic phospholipid DOTAP but a detailed characterization of this interference 
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was not undertaken. Therefore, cell viability levels were verified for each liposomal 
formulation using flow cytometry analysis following Annexin V/PI staining.  
The apoptosis-inducing influence of AFT loaded-PSL formulation was evidenced by 
Annexin V/PI protocol. The extent and the nature of the induced cell death were 
analyzed by flow cytometry. H-1975 cells were incubated with various concentrations 
of PSL (0.5 - 8 µM) for 24 h, which were selected based on WST-1 assay results. The 
amounts of the early apoptotic and the late apoptotic cells, with necrotic cells were 
determined after deduction of the proportion of spontaneous apoptosis. The results 
clearly reveal that the PSL triggered apoptosis in H-1975 cells (Figure 3- 3A).  
The results indicated a marked decline in cell viability following treatment with PSL, 
compared with AFT solution, indicating that liposomes can improve the therapeutic 
efficacy of AFT in NSCLC. Liposomes have emerged as an important potential drug 
delivery vehicle for chemotherapy drugs and small molecule compounds in tumor 
therapy application [72].  The IC50 of PSL was 26 times lower than that of free AFT 
(Figure 3- 3). The absence of a strong cytotoxic effect of drug solution could be due 
to a low intracellular drug concentration, which may result from low cellular drug 
uptake due to poor trans-membrane permeability, or even due to drug efﬂux. These 
results are generally in agreement with those obtained by Guan et al. who found that 
treatment of human colorectal cancer HCT-15 cells with AFT encapsulated micelles 
showed a higher decrease in the cell viability than treatment with AFT alone. 
However, micelles alone showed the non-cytotoxicity of the materials in HCT-15. 
Also,  flow cytometric analysis indicated that cell apoptosis was significantly 
increased in AFT/micelle-treated tumor cells as compared with AFT alone [220]. 
Of the three cancer cell lines tested, H-1975 cells appeared to be more sensitive to the 
liposomal formulation as relatively lower drug concentrations effectively induced 
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cytotoxicity. These results suggest that NSCLC cells with T790M mutant EGFR are 
relatively more sensitive to AFT than cells carrying wild-type EGFR, which is 
consistent with the results from earlier studies [221, 222]. Ninomiya1 et al., 
investigated the in vitro efﬁcacy of AFT against tumor cells with activated EGFR 
mutations with or without the T790M mutation. They found that the presence of AFT 
significantly increased the cell killing effect in PC-9- GR cells harboring acquired 
T790M  [222]. Moreover, they found that AFT was more potent than gefitinib in the 
treatment of lung adenocarcinoma with an EGFR exon 19 deletion mutation. Also, 
Zhang et al reported that NSCLC cells with T790M mutant EGFR are relatively more 
sensitive to AFT than cells carrying wild-type EGFR [221]. 
It is possible that PSL released AFT in response to the lower pH environment in the 
endosome, and thus facilitated diffusion of the released AFT from the endosome to 
the cytosol. One possible mechanism of such facilitated diffusion could be the 
destabilization of endosomal membranes generated from the destruction of liposomes. 
It has been suggested that pH-sensitive liposomes are internalized more efficiently 
than non-pH-sensitive formulations [223, 224]. In this context, it is noteworthy that 
studies on the destabilization of liposomes at the endosomal level and investigations 
involving the incubation of cells with lysosomotropic agents (e.g. ammonium chloride 
or chloroquine, which prevent endosome acidification) demonstrated that the efficacy 
of pH-sensitive liposomes depends on the pH decline following endosome maturation 
[84]. Additionally, various kinetic studies have shown that liposomes composed of 
DOPE/OA, DOPE/palmitoylhomocysteine, DOPE/dipalmitoylsuccinylglycerol or 
CHEMS [179] release their contents into the cytoplasm over a period of time that 
ranges from 5-15 min post incubation with the cells, thus signifying that cytoplasmic 
delivery occurs from early and late endosomes. These observations suggest that the 
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fusion or destabilization of liposomes induced by acidification of the endosomal 
lumen represents the most important stage in the process of intracellular delivery. 
However, the molecular mechanisms underlying how liposomes can overcome the 
barriers presented by the cytoplasmic and endosomal membranes to release their 
contents into the intracellular space remain to be clarified. Carvalho et al developed 
cisplatin pH-sensitive liposomes (DOPE/CHEMS/DSPE-PEG) to treat SCLC [225]. 
Compared with free cisplatin, the cytotoxicity of this PSL was significantly enhanced. 
Furthermore, this approach is effective for cells that are tolerant/resistant to cisplatin 
[225]. Kim et al developed a PSL with an EGFR antibody attached, which was 
designed and tested using A549 cells and a BALB/c-nu/nu mouse tumour model. They 
found that PSLs provide an efficient and targeted delivery system for gemcitabine, 
and may represent a useful, novel treatment approach for tumours that overexpress 
EGFR [226].  
To understand the response of NSCLC cells to PSL NPs therapeutics, a quantitative 
proteomic approach was used to study the protein expression profiles of NSCLC cells 
treated with AFT. The results show significantly differentially expressed proteins 
from both treated and control H1975 and H1650 NSCLC cells demonstrating the 
ability to discriminate treatment effects between the sample groups.  
The strategy of differential gene expression changes provides a unique possibility to 
identify treatment-related biomarkers from different types of NSCLC thus providing 
insights into the possibility of translating these findings into humans. 
Differential protein expression changes across different types of NSCLC cells were 
used to accurately classify the samples into different treatment sub groups. Thus, the 
expression of the 385 protein changes across the four sample groups were further 
evaluated for their associations with cancer. The analysis of the identified proteins is 
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composed of cancer- related networks and have been implicated in NSCLC. This 
means, that it will be challenging that one panel of biomarker proteins will have 
similar changes across different cell types. Hence a protein dataset might need to be 
created for each specific treatment cell types. 
Interestingly, a review of literature indicated that 15 molecules that were implicated 
in the IPA analysis in one of the networks as shown in Figure 3- 8 have been associated 
with NSCLC. The analysis of the identified proteins is composed of cancer- related 
networks some of the associated molecules in pink color have been implicated in 
NSCLC. This demonstrates the power of proteomics in the  identification of 15 
potential biomarkers in one study that have previously been described in different 
individual studies using different analysis platforms [227, 228]. 
Even though some of these potential biomarkers have been singly described, these 
findings indicate that rather than the use of a single marker, analyses of a panel of 
protein markers has the potential to provide better insights and understanding of a 
particular treatment response on NSCLC cells. There is still a limitation in translating 
the findings of this in vitro study into humans, as markers of treatment responses. 
However, these molecules could be validated using other methods such as 
immunohistochemistry and possibly using an animal model prior to translation into 
humans. 
Targeting the tumor metabolism via anti-glycolytic treatments can be a therapeutic 
option as it considers an important converging step for multiple deregulated signaling 
pathways in cancer cells. Lactate dehydrogenase-A (LDHA) catalysis the 
interconversion of pyruvate and L-lactate and also regenerates NAD+, which is 
essential for the continued high glycolysis rate in cancer cells [229].  LDHA plays an 
important role in the development, invasion and metastasis of malignancies, including 
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lung cancer [230]. LDHA is overexpressed in NSCLC tissues which is linked to tumor 
hypoxia, angiogenic factor production and poor prognosis [231]. Fantin et al. proved 
that tumor cells depend on LDHA activity, while  nonmalignant cells depend on the 
oxidative phosphorylation system, by showing that growth of LDHA-deficient tumor 
cells was reduced in mouse Neu4145 mammary gland tumor cells even under hypoxic 
conditions (0.5% oxygen) [232]. 
Adenylate cyclase-associated protein 1 (CAP1) is one of the major actin-regulating 
proteins in cancers [233] and the role of CAP1 in the proliferation and differentiation 
of cancer cells has been paid much consideration [234]. A study by Tan et al assessed 
the diagnostic and prognostic value of CAP1 for lung cancer using real-time PCR and  
Western blot analysis and/or immunostaining in biopsy specimens of lung cancer and 
in cultured lung cancer cells. They found that overexpression of CAP1 in lung cancer 
cells, mainly at the metastatic stage, may have important medical implications as a 
diagnostic/prognostic factor for lung cancer [235]. It has been found that expression 
of CAP1 was significantly higher in NSCLC tissues as compared to the corresponding 
normal lung tissues and there is connection between the tissue protein CAP1 level and 
the stage of NSCLC [228, 233]. 
One of the most important proteins is TGFβ1 (Figure 3- 8), a multifunctional cytokine 
that widely involved in the adjustment of life activities, such as proliferation, 
differentiation, migration, and apoptosis [236]. At present, an increasing number of 
researchers have showed that the TGF-β signaling pathway is related to tumor 
progression [237-239]. The TGFB1 expression may be a predictive biomarker for the 
risk of developing metastasis in non-small cell. Importantly, increased TGFb1 
expression and increased serum levels are linked with progression of lung cancer in 
patients with NSCLC [187, 188, 240-242]. Interestingly, Sang et al demonstrated that 
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polymorphism of the TGFB1 gene was linked with clinical progression of NSCLC 
patients and might be a predictive marker for NSCLC prognosis [154]. These data 
indicate that TGFb1 (Figure 3- 8) is at the center of the network interacting with all 
these molecules.  Therefore, expression of these molecules may be predictive 
biomarkers for the risk of developing metastasis in non-small cells.  
3.7. Conclusion  
The obtained results revealed the efficiency of AFT as potent cytotoxic drug (IC50 
value; 20 µM) compared to other drugs commonly used for lung cancer treatments. 
Also, AFT-loaded liposomes showed enhanced cytotoxicity on cancer cells (NSCLC). 
The PSL inhibited the cell growth of lung cancer cells more efficiently than CL, NL 
and free AFT based on using Annexin V assay. The PSL produced the highest 
cytotoxic effect in the different lung cancer cell lines. Also, the identified protein 
signatures have been capable of prediction of treatment response and choice of therapy 
for two different types of human NSCLC cells (H1975 and H1650) using expression 
proteomics as biomarker discovery for treatment options. These findings lend further 
support to the efficacy of PSL NPs in treatment of NSCLC harboring EGFR 
mutations, and the identification of a new biomarker in lung cancer will provide a 
theoretical basis for clinicians and researchers to develop a new therapeutic approach 
for NSCLC.  
All together, these data indicate that PSL NPs is a promising targeted drug delivery 
for NSCLC and should be further investigated for incorporation of PSL NPs into 
micron-scale structures NCMPs via spray drying.  
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Formulation of Afatinib Loaded 
Nanoparticles as Aerosolizable 
Microcarriers 
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4.1. Introduction 
Local administration of nanoparticulate chemotherapeutic agents to the respiratory 
tract of patients with NSCLC is a promising therapeutic technique [243]. Inhalation 
therapy can play an important role in the fight against cancer by delivering 
chemotherapeutic drugs locally to the lung tumor cell and thus; reduce systemic 
exposure to the drugs, enhance exposure of tumor tissue to the drug, and reduce 
systemic side effects [61]. One approach for delivering chemotherapeutic drugs to the 
lung is the use of DPIs, owing to their advantages over pressurized metered dose 
Inhalers (pMDIs), such as being breath-activated and having no requirement for 
propellant [16, 244]. 
Several studies have demonstrated the applicability of liposomes for the pulmonary 
delivery of a large variety of drugs such as; anti-asthmatic drugs, cytotoxic agents, 
and drugs for systemic action [245]. However, there are some drawbacks with 
liposomal formulations that can restrict their commercial use such as  high 
manufacturing cost and instability during storage, even at low temperatures [246].  
One strategy to increase the stability of liposomes is spray drying (SD). The SD 
process is an attractive solidification technique in the field of drug delivery, due to its 
relative simplicity, the ability to produce a homogenous particle size distribution, the 
availability of large-scale equipment, and the capability to control several parameters 
to optimize the particle characteristics such as shape, morphology, size, size 
distribution, and density [247]. Accordingly, it can be used to produce dry powders 
for inhalation.  
The pulmonary delivery of NPs requires incorporation into microcarriers, of between 
1 to 5 μm, consisting of NPs and inert pharmaceutical excipients, such as sugars, 
amino acids, or phospholipids. Delivering NPs within nanocomposite microparticles 
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(NCMPs), directly to the lungs via DPI, offers many advantages. These include; the 
elimination of potential drug  degradation in the low pH environment of the stomach, 
reduced exposure to proteolytic enzymes, and the improved physical and chemical 
stability as a  dry formulations [248]. 
Biocompatible excipients (carbohydrates, amino acids, and lipids) are generally added 
to the formulation feed to produce dry powders of a desirable aerodynamic particle 
size that will rapidly release the NPs upon contact with the lung fluid lining [255]. 
Additionally, the excipients will impart some level of protection to both the NPs and 
encapsulated drug during SD, against the high shear forces and the elevated 
temperatures used, and offer stability during storage [249].   
L-leucine (LEU) is an example of an amino acid excipient that is commonly used in 
the pharmaceutical industry due to its potential to improve the bioavailability and 
dispersibility of aerosols. Spray drying of a LEU solution produces corrugated 
particles with low density which  improves the aerosolization of the incorporated 
species [250]. 
Chitosan (CH) is a cationic mucoadhesive polymer derived from the natural polymer 
chitin, one of the most abundant polysaccharides in nature [251]. Chitosan has been 
widely used in drug delivery research  because of its biocompatibility, 
biodegradability, very low toxicity and its potential to be chemically modified [252]. 
Recently, particulate carriers based on CH and its derivatives have been extensively 
investigated for pulmonary delivery of various therapeutic drugs and proteins [253-
255]. Due to its mucoadhesive properties, permeation-enhancing effect, controlled 
release properties, and capability to open tight junctions between epithelial cell, CH 
is a promising material for countless DDS [255-257]. Chitosan can significantly 
enhance the adsorption of therapeutic agents to mucosal surfaces [258, 259] and 
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improves the dispersion characteristics of dry powders [251], offering several  
important advantages for the pulmonary delivery of macromolecules locally in the 
lung or systemically upon absorption through the alveolar region [260, 261].  
Chitosan can be formulated as  powders or well-structured micro and nanocarriers that 
can be engineered to have optimal aerodynamic particle diameters for deep lung 
deposition and prolonged retention [262]. The mucoadhesive properties of CH  are 
due to the molecular attractive forces formed by the electrostatic interaction between 
the positively charged CH  molecules and the negatively charged mucosal surfaces 
[263, 264].There are several examples in the literature of the successful spray-drying 
of liposomes using different carriers. Cationic liposomes spray dried with and without 
paclitaxel using trehalose as carrier indicated that liposomes were well retained after 
SD under different drying conditions and the protective effect of trehalose was very 
important at high inlet temperatures [206].  Charnvanich et al.  studied the effect of 
cholesterol on the encapsulation efficiency and physical characteristics of spray dried 
liposomes [265]. Cholesterol enhanced the encapsulation and reduced the diameter of 
the reconstituted liposomes. A stable, spray dried preparation of CH  coated liposomes 
was also prepared using maltodextrin as an excipient [266]. Liposomes composed of 
soybean PC (SPC) were spray dried in the presence of lactose at an inlet temperature 
of 110 °C and an outlet temperature of 75 – 80 °C and dispersed in water to rehydrate 
liposomes without major changes in the vesicle size distribution. Moreover, the 
chemical stability (hydrolysis and oxidation) of the phospholipids was not 
significantly affected by this process [264]. A study by Hauser and Strauss,  reported 
that 90% of  the entrapped hydrophilic model compounds (raffinose and KFe(CN)) 
remained encapsulated in small unilamellar palmitoyloleoylphosphatidylcholine 
(POPC) /  dioleoylphosphatidylserine (DOPS) vesicles after SD and rehydration, by 
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applying sucrose as a stabilizer at an inlet temperature of 140°C and an outlet 
temperature of 67°C [266]. Lo et al, showed that the use of 
Dipalmitoylphosphatidylcholine (DPPC), a natural lung surfactant, with sucrose 
showed good results for the liposomal preparation of superoxide dismutase enzyme, 
efficiently protecting the enzyme from degradation and loss of activity [267]. 
Moreover, the formulation demonstrated good powder aerosolization  with mean 
particle sizes of 3 µm [267]. Chougule et al. evaluated liposomal encapsulated 
Dapsone in a dry powder inhaler, reporting in vitro prolonged drug release up to 16 h 
[268]. Liposomal tacrolimus was reported to have a prolonged residence time of up to 
24 h within the lungs. Also, the stability of liposomal tacrolimus embedded in a 
trehalose matrix, for six months at 40 °C / 75 % RH, showed an increase in liposome 
size, a decrease in Fine Particle Fraction (FPF) and prolonged retention at the lung 
[268].   
 
4.2. The aim of the Study 
The aim of this study was to develop a suitable formulation for the dry powder 
delivery of AFT-liposomes to the deep lung.  
In this study, pH sensitive liposome (PSL) NPs (optimized in chapters 2 and 3) 
encapsulating AFT were incorporated into microparticle carriers via SD to produce 
PSL NPs/NCMPs as DPIs suitable for pulmonary delivery.  
The aim of the study was achieved by the following objectives to:  
1. Incorporate optimum PSL NPs into NCMPs via spray drying with L-leucine as a 
dispersibility enhancer. 
a. Optimize NCMPs formulations in term of size and yield%.  
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2. Formulate NCMPs using CH containing the optimum ratio of LEU to generate 
highly respirable powders. 
a. Evaluate the effect of different ratios of CH on the morphology, particle size, 
yield %, and drug content of NCMPs.  
b. Investigate NPs size recovery from NCMPs and the release of AFT from 
NCMPs vs NPs.  
c.   Study the in vitro aerosolization behavior and cell toxicity of the optimal coated 
NCMPs.  
d.   Determine the stability of the coated NCMPs. 
 
4.3. Materials and Methods 
4.3.1. Materials 
AFT (99.8% purity) was purchased from Green Stone Swiss Co., Limited. Triton X-
100, Triethylamine, Sodium hydroxide pellets, L-leucine, Chitosan poly (D-
glucosamine) Deacetylated chitin low molecular weight, and Acetic acid glacial were 
purchased from Sigma-Aldrich, Saint Louis, USA. All other reagents and chemicals 
were of analytical grade. 
4.3.2. Methods 
4.3.2.1. Synthesis and characterization of pH sensitive liposome 
nanoparticles  
The pH sensitive liposomes (PSL NPs) was synthesized and characterized as 
described earlier in sections 2.3.2. and 2.3.3, respectively. 
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4.3.2.2. Preparation of nanocomposite microparticles  
4.3.2.2.1. Preparation of nanocomposite microparticles using L-leucine 
(LNCMPs). Nanocomposite microparticles (NCMPs) of PSL NPs were prepared by 
SD using LEU as a carrier at different lipid: carrier ratios (w/w).  A quantity of PSL 
NPs was dispersed in LEU solution (10 mL) at lipid: LEU ratios of 1:0.5, 1:1, and 
1:1.5 w/w, and spray dried using a Büchi B-290 mini spray-dryer (Büchi 
Labortechnik, Flawil, Switzerland) with a nozzle atomizer, and nozzle orifice 
diameter of 0.7 mm. The spray drying was performed at a feed rate of 10%, an 
atomizing air flow of 400 L/h, aspirator capacity of 100% and an inlet temperature 
of 100°C (outlet temperature approximately 30–35°C). The dry NCMPs were 
separated from the air stream via a high-performance cyclone (Büchi Labortechnik), 
collected and stored in desiccator room temperature until further use.  
4.3.2.2.2. Preparation of coated nanocomposite microparticles using L-leucine 
and chitosan (CNCMPs) 
Appropriate amounts of LEU and CH were dissolved under stirring in distilled water 
or acetic acid (0.1%) aqueous solution, respectively. A quantity of PSL NPs was 
dispersed in the LEU solution (lipid: LEU ratio of 1:1.5 w/w) with stirring at 25◦C 
for 1 min and then the CH solution was added at different CH ratios (CNCMPs). 
The lipid: LEU: CH ratios are; 1:1.5:0.5 (C1NCMP), 1: 1.5:1 (C2NCMP), 1: 1.5:1.5 
(C3NCMP) and 1: 1.5:2 (C4NCMP) (w/w)) and stirred for 5 min at 25◦C to maintain 
homogeneity. The dispersions were spray dried as stated in section 4.3.2.2. 
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4.3.3. Characterization of nanocomposite microparticles 
4.3.3.1. Particle size and zeta potential of the reconstituted liposomes 
The reconstituted liposomes were characterized for particle size, polydispersability 
(PDI), and zeta potential as described previously in section 2.3.3.1. Before 
measurements, 5 mg of spray dried powders was dispersed in 10 mL distilled water 
with vortexing for 5 minutes. 
4.3.3.2. Morphology and size of nanocomposite microparticles 
The surface morphology of NCMPs was determined using a Field Emission Scanning 
Electron Microscope (JSM-6060LV, JEOL Scaning Electron Microscope, Japan). A 
thin layer of NCMPs was fixed on carbon adhesive tape on an aluminium stub. The 
sample was sputter coated with platinum under argon atmosphere at 180 mA for 1 
min using the autofine coater (JEC-3000FC, JEOL Japan). Photographs of the spray 
dried powders were taken by random scanning of the stub.  
Five milligrams of the spray dried powders were suspended in 2 ml deionized water 
and immediately measured by laser diffraction [269], using a Zetasizer Nano ZS 
(Malvern Instruments, UK) at 25°C (n=3), to determine the geometric particle size by 
laser diffraction using a Zetasizer Nano ZS (Malvern Instruments, UK). 
For scanning electron microscopy (SEM) the spray-dried powders were coated with 
gold in a sputter coater and their surface morphology was observed using a scanning 
electron      microscope (JEOL 6500F field emission scanning electron microscope; 
Tokyo, Japan). 
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4.3.3.3. Nanocomposite microparticle yield 
The yield of spray dried NCMPs powders were computed as the percentage mass of 
expected total powder yield according to the following equation [270]: 
𝑌𝑖𝑒𝑙𝑑 % =  ௐ௘௜௚  ௢௙ ௗ௥௬ ௣௢௪ௗ௘  ௖௢௟௟௘௖௧௘ௗ ௔௙௧௘௥ ௦௣௥௔௬ ௗ௥௬௜௡௚
ௐ௘௜௚௛௧ ௢௙ ௧௢௧௔௟ ௗ௥௬ ௠௔௦௦ ௨௦௘ௗ ௙௢௥ ௧௛௘ ௣௥௘௣௔௥௔௧௜௢௡
× 100     Equation 4-1   
4.3.3.4. Flow Properties and primary aerodynamic diameter  
4.3.3.4.1. Angle of repose 
The fixed funnel method was used for calculating the angle of repose for different 
powder formulations. The angle of repose (θ) was measured to determine the powder 
flowability and determined by the method described by Huang et al [271, 272]. 
4.3.3.4.2. Powder density  
The powder density was evaluated using the tapped density measurement. The tapped 
density was determined from the volume occupied by a known mass of powder in a 5 
ml measuring cylinder after tapping the measuring cylinder from a constant height 
until no further change in powder volume was observed [276]. Measurements were 
performed in triplicate (n= 3). 
4.3.3.4.3. Aerodynamic diameter 
The theoretical primary aerodynamic diameter (dae) was calculated using data 
acquired from geometric particle size (d) and tapped density(ρ) according to the 
following equation [273]:  𝑑௔௘ = 𝑑 ට
ఘ
ఘଵ
                                   Equation 4-2  
ρ1 = 1 g/cm3  
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4.3.4. Drug content  
The spray dried samples (10 mg) were dispersed into 5mL PBS at pH 5.5 and 
sonicated for 5 min before adding 5mL methanol, vortexing for 1 min, and then 
filtering through a 0.22 µm membrane filter. The AFT content was determined by 
HPLC as previously described in section 2.3.4.  
4.3.5.   In vitro aerosolization studies  
The aerodynamic particle size of the CNCMPs was assessed using a Next Generation 
Impactor (NGI) (Copley Scientific, UK) (Figure 4- 1). The NGI has a range of cut off 
diameters at 60 L/min, with particles captured on any specific stage having an 
aerodynamic diameter less than the previous stage, assuming ideal collection behavior 
on each stage, using a low resistance DPI Cyclohaler® (Teva pharma) inhaler.  
The DPI flow resistance is a fixed property that determines the air flow rate through 
the inhaler in response to the inspiratory effort of the patient.  Each inhaler has a 
unique resistance and current inhalers have a wide range of resistance values.  The 
maximum flow rate generated by the patient is affected by the resistance of the device, 
which is closely linked to the structure and mechanism of deaggregation. The higher 
the resistance of the DPI, the higher is the force needed to ensure a sufficient pressure 
drop within the device and the lower the maximum flow rate [274]. 
The CNCMPs samples were weighed (4 triplicates, each corresponding to 10-15 mg 
spray-dried powder) and manually loaded into hydroxypropyl methylcellulose 
capsules (size 3) and aerosolised via a low resistance DPI Cyclohaler® (Teva pharma) 
into NGI. The capsule was punctured using the actuator of the Cyclohaler® prior to 
inhalation and a pump (Copley HCP5, Copley Scientific, UK) was used to simulate 
inspiration (the flow rate was 60L/min for 4-5s). Prior to testing, the preseparator was 
filled with 15ml of mobile phase solution A (0.1% triethanolamine and 1% acetonitrile 
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in HPLC water (pH=6)) and the NGI stages were coated with 1% tween 80: methanol 
solution to eliminate particle bounce [275]. One capsule was emptied in each of the 4 
runs.  
Following aerosolization, the samples were collected from each stage of the NGI, pre-
separator, throat, mouth piece, inhaler, and capsule by washing with a PBS/methanol 
mixture (50%) to dissolve the polymer and the encapsulated AFT, which was 
determined by HPLC as described in section 2.3.4.  
The emitted dose (ED) was determined as the sum of powder deposited in the 
mouthpiece, throat, pre-separator, NGI stages and micro-orifice collector of the NGI 
(MOC). The fine particle dose (FPD was determined as the sum of powder deposited 
in NGI stages and MOC with aerodynamic diameters less than 4.6 μm. The FPF% 
was determined as the fraction of ED deposited in the NGI and MOC with 
aerodynamic diameters less than 4.6 μm. The mass median aerodynamic diameter 
(MMAD) and geometric standard deviation (GSD) were determined using online 
software (MMAD calculator.com).  
4.3.6. In vitro release    
The CNCMPs samples (10 - 15 mg) were placed in micro tubes, dispersed in 1 ml of 
PBS (pH 5.5) containing 0.2% tween 80, incubated at 37 °C and rotated at 20 rpm in 
a sample mixer (HulaMixer, Invitrogen Dynal AS, Life Technologies).  At 
programmed time intervals, up to 24 h, the samples were centrifuged (Sigma 3-30k, 
Fixed-angle rotor 12110, SIGMA Laborzentrifugen GmbH, Germany) at 20,000 rpm 
for 30 min) and 0.5 ml of the supernatant removed and replaced with fresh buffer 
contained 0.2% tween 80 and vortexed for 1 min. The supernatant was analyzed by 
HPLC as described in section 2.6 (n=3).  
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4.3.6.1. Kinetic modelling  
Kinetic modeling was carried out as described in section 2.3.5.1. 
 
4.3.7. Cytotoxicity assessment using flow cytometry 
The cytotoxicity of NCMPs was determined as described in section 3.3.2.3.2.     
4.3.8. Stability of dry powder 
The CNCMPs powders were stored for 3 months. Freshly prepared spray dried 
samples were filled into glass vials and placed in a desiccator and stored at accelerated 
conditions (40 °C ± 2 °C, 75% ± 5% RH) as stated by ICH guidelines [276]. The spray 
dried samples were retested after 0, 2, 4, 8, and 12 weeks with respect to liposome 
size, PDI, zeta potential and drug content as described in 4.3.3.1. and 4.3.4. The 
samples were also examined visually for any evidence of caking or discoloration. 
Figure 4- 1: NGI with induction port and preseparator (Source: Copley Scientific 
Limited, UK). 
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4.3.9. Statistical analysis 
Quantitative data were expressed as the mean ± SD of at least three replicates. The 
Student’s t-test and one-way analysis of variance (ANOVA) using IBMSPSS 
Statistics 21 was used to assess multiple comparisons between different methods and 
times. The level of confidence was set as 95%.  
4.4. Results 
4.4.1. Characterization of spray dried NCMPs using L-leucine.  
Spray-drying was used to incorporate the selected PSL NPs into NCMPs using LEU 
as a carrier and to improve powder dispersion.  The geometric particle size of the 
LNCMPs was in the range of 2.60 - 4.85 µm. The yield of LNCMPs (dry powder) 
was between 50 and 60 % (Table 4- 1). Photomicrographs of the L3NCMPs (at lipid: 
LEU ratio of 1:1.5) showed an irregular and corrugated surface (Figure 4- 2). It was 
noticed that a mass ratio of 1:1.5 produced the highest yield. Therefore, this ratio was 
selected for further SD studies using CH. The liposomal size increased after 
reconstitution to 60.77 nm with minimal change in zeta potential. 
 
Table 4- 1: The mean particle size and yield % of the NCMP using L-leucine alone. 
(mean ± S.D., n=3). 
Code 
 
Lipid:L-leucine 
ratio 
Geometric Particle 
 size (µm) ± SD Yield (%) ± SD 
L1NCMPs 1: 0.5 2.60 ± 5.3 50.1 ± 2.2 
L2NCMPs 1: 1 3.20 ± 2.7 54.6 ± 3.5 
L3NCMPs 1: 1.5 3.57 ± 3.7 60.2 ± 2.8 
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4.4.2. Characterization of spray dried NCMPs using L-leucine and 
chitosan  
4.4.2.1. Production yield  
The dry powder yield ranged from 62.1 to 71.8 %.  Table 4- 2 shows the values of the 
yield obtained after SD. The lowest mean yield was obtained for C4NCMPs, at lipid: 
LEU:CH 1:1.5:2 w/w, (63.8 ± 4.3 %) and the highest was obtained for C1NCMPs (at 
lipid: LEU:CH 1:1.5:0.5 w/w) formulation (71.8 ± 3.5 %). As seen in Table 4- 2, there 
was a gradual decrease in the production yield, with increasing the CH ratio.  
4.4.2.2. Powder Properties and primary aerodynamic diameter  
The CNCMPs had a geometric particle size in the range of 3.61 –5.39 μm (Table 4- 
2). The tapped density was found to be in the range of 0.3 – 0.6 g/cm3 and this was 
used together with the geometric particle size to calculate the theoretical aerodynamic 
diameter within the respirable range (2.8 – 3.23 µm). The angle of repose for the 
formulations fell in the range of 28 to 29 degrees.  
Figure 4- 2: SEM images of spray drying of PSL NPs using L-Leucine at lipid: 
leucine ratio of 1:1.5. 
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4.4.2.3. Morphology 
The morphology of the coated NCMPs was evaluated by SEM and a selection of 
microphotographs is presented in Figure 4- 3. The microparticles had wrinkled 
surface, which look like raisins but by increasing the ratio of CH, more homogenous 
and smooth particles with some small indentations were obtained.  
 
 
Table 4- 2: The geometric particle size, yield %, tapped density, angle of repose, and 
theoretical aerodynamic diameter of NCMPs prepared by spray drying of PSL NPs 
using L-leucine at lipid: LEU ratio of 1:1.5 w/w and different ratios of chitosan. Mean 
± S.D, (n=3). 
 C1NCMPs C2NCMPs C3NCMPs C4NCMPs 
        Ratio 
(Lipid: LEU:CH) 
1:1.5:0.5 1: 1.5:1 1: 1.5:1.5 1:1.5:2 
Geometric  
particle size (µm) 
3.61±0.19 4.17±0.14 4.93±0.73 3.40±0.35 
Yield (%) 
 ± SD 
71.8±3.5 67.2±5.3 64.8±4.9 63.8±7.9 
Tapped density  
(g/cm3) 
0.35±0.013 0.40±0.018 0.43±0.019 0.27±0.021 
Angle of repose 28.8±0.2 29.1±0.5 29.1±0.4 27.5±0.7 
Flow propertied Excellent flow 
dae (µm) 2.14±0.1 2.64±0.1 3.23±0.3 2.80±0.2 
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Figure 4- 3: SEM photographs of liposomes spray dried in the presence of L-Leucine 
and different ratios of chitosan (at lipid: Leu:CH ratio of 1:1.5:0.5 (C1NCMP), 1: 
1.5:1 (C2NCMP), 1: 1.5:1.5 (C3NCMP) and 1: 1.5:2 (C4NCMP) (w/w)). Pictures 
were taken at 4000× and 25000× magniﬁcations. 
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4.4.2.4. Particle size and zeta potential of reconstituted NCMPs  
The size of PSL NPs after recovery from spray dried CNCMPs powders increased 
significantly (P < 0.05) compared to the size of pre-spray dried liposomes.  Spray 
drying of CNCMPs with CH induced a substantial increase in average particle size 
and zeta potential of the developed microparticles (Table 4- 3). The average size of 
liposomes was between 62.4 - 89.4 nm, which is larger than the original liposomes, 
with low poly dispersibility index. The lower the ratio of the CH, the smaller the size 
of liposomal vesicle. The difference in mean particle size (approximately 20 nm ± 
7.23) was not signiﬁcant for the ratios of 1:0.5 and 1:1 but was signiﬁcant (by > 40 
nm ± 11.45) for ratio of 1:2 (P < 0.05).  The surface charge of reconstituted liposomes 
changed when CH used toward positive values (Table 4- 3). The zeta potential of 
CNCMPs was dependent on CH ratio; at low CH ratio (C1NCMPs), the zeta potential 
increased (-14 mV). When CH ratio was increased to the highest ratio (C4NCMPs) 
zeta potential changed to -8.46.  
 
Table 4- 3: The mean particle size, polydispersity index, and drug content of the 
reconstituted CNCMPs using chitosan.  (Mean ± S.D., n=3). 
                               Ratio 
                      (Lipid:LEU:CH) 
Particle 
size (nm) 
± SD 
PDI ± SD Zeta 
Potential 
(mV) ± SD 
Drug 
content 
% 
C1NCMPs 1:1.5:0.5 60.4±3.2 0.240±0.01 -14±0.2 92.5±3.9 
C2NCMPs 1:1.5:1 70.2±2.4 0.227±0.01 -11.6±0.1 89.7±4.8 
C3NCMPs 1:1.5:1.5 84.6±3.1 0.237±0.06 -9.8±0.1 89.4±5.1 
C4NCMPs 1:1.5:2 89.4±2.8 0.164±0.06  -8.5±0.2 87.2±2.3 
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4.4.3. Aerosolisation  
 The FPF and FPD values show the fraction and the amount of AFT particles reach to 
the lower respiratory tract. Among the formulations prepared, increasing the ratio of 
lipid: CH made a significant change on FPF values (P ˂ 0.05).  C1NCMPs produced 
higher FPD and FPF %, 40 µg 51.2 % respectively, and this was attributed to the more 
porous structure of the NCMPs. In contrast, C4NCMP powders have the lowest FPF% 
of 33.7 % and MMAD with smaller MMAD (3.2 µm). All prepared formulations have 
MMAD values in the optimal size range of 3.2–5.9 μm. Also, more than 50% (FPF) 
deposition in respirable airways (1-5 um) delivered 40 µg dose (FPD), i.e. 40 µg 
deliver from the delivery system, which contain 100 µg dose was, and deposited in 
the target site.   
 
 Table 4- 4: The Fine particle dose (FPD), percentage fine particle fraction (FPF), and 
mass median aerodynamic diameter (MMAD) of NCMPs. (mean ± S.D., n=3). 
 
                               Ratio 
                      (Lipid:LEU:CH) FPD
a(µg) FPFb(%) 
MMADc 
(µm) 
C1NCMPs 1:1.5:0.5 40.0 ± 4.2 51.2 ± 2.2 4.8 ± 0.1 
C2NCMPs 1:1.5:1 33.7 ± 5.2 45.9 ± 5.7 4.2 ± 0.8 
C3NCMPs 1:1.5:1.5 31.7 ± 2.8 40.9 ± 2.4 5.9 ± 0.7 
C4NCMPs 1:1.5:2 28.4 ± 4.6 33.7 ± 4.9 3.2 ± 0.7 
aFine particle dose (FPD)  
bFine particle fraction (FPF) 
cMass median aerodynamic diameter (MMAD) 
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4.4.4. In Vitro Release Studies 
The % cumulative AFT released in vitro from NCMPs is presented in Figure 4- 4. The 
release, of the reconstituted NCMPs, in a PBS (pH 5.5) showed a delayed drug release 
compared to PSL NPs. The drug release was 15 % and 4.3 % within 2h and 72.2% 
and 46.3% after 12 h, and 89.4 % and 67.4 % over 24 h for C1 NCMP and C4 NCMP, 
respectively. All systems show the best correlation with the Higuchi and anomalous 
(non-Fickian) diffusion models (n > 0.5) (Table 4– 4).   
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Figure 4- 4: In-vitro release of afatinib from NCMPs and pH sensitive liposomes (PSL) 
in PBS buffer (pH 5.5) at 37°C. (Mean ± S.D., n=3). 
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Table 4- 5: The kinetic parameters of afatinib from CNCMPs prepared by spray   
drying of PSL NPs using L-leucine at lipid: LEU ratio of 1:1.5 w/w and different ratios 
of chitosan.  
 C1 NCMP C2 NCMP C3 NCMP C4 NCMP 
Zero- Order 
r2 0.932 0.935 0.894 0.862 
ko (h-1) 1.872 1.859 2.467 2.251 
First- Order 
r2 0.953 0.977 0.933 0.875 
k1 (h-1) 4.560 4.565 4.531 4.546 
Higuchi 
r2 0.978 0.983 0.966 0.922 
k1 (h-½) 10.170 9.957 13.891 12.285 
Korsmeyer-
Peppas 
r2 0.957 0.982 0.954 0.925 
N value 0.790 0.679 0.675 0.682 
kKP (h-n) 0.0450 0.0559 0.0829 0.0554 
 
4.4.5. Stability study 
The stability of CNCMPs was studied to monitor the influence of storage conditions 
on their physiochemical characteristics and percent drug content. Figure 4- 5 
represents the liposome size after the rehydration of spray dried powders. At the 
beginning, the liposome size was between 62.43 and 89.54 nm for C1NCMP and 
C4NCMP, respectively and the PDI > 0.327. All measurements revealed a liposome 
size in the range of 97.85 – 108 nm after 4 weeks of storage. Aside from minor 
fluctuations, after 8 weeks there were no significant increase in the sizes of all 
powders. After 12 weeks, only one powder showed size > 121 nm and almost all 
reconstituted powders were cloudy, the liposome PDI was > 0.44. Zeta potentials of 
the reconstituted liposomes dispersions at different times are displayed in Figure 4- 6. 
The measured zeta potentials were between - 14 and -4.9 mV. Zeta potentials were 
constant regardless of the size measured. When exposed to high temperature and 
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humidity, AFT content was reduced in all powders. After 12 weeks AFT contents 
were reduced from 92.5% to 2% in C1NCMP and 87.2% to 0.93% in C4NCMP 
(Figure 4- 7). A discoloration in all powders was noticed upon storage, ranging from 
a light-yellow to dark-yellow coloration depending on CH ratio, yellowing was not 
seen in the control specimens.  
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Figure 4- 5: The effect of time on the reconstituted mean liposomes size stored at 40°C. 
(Mean ± S.D., n=3). 
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Figure 4- 7: Drug content % of NCMPs, following storage for different periods at 40°C, 
75% ± 5% RH. (mean ± S.D., n=3). 
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Figure 4- 6: Reconstituted Liposome mean zeta potential at different time stored at 40°C. 
(Mean ± S.D., n=3). 
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4.4.6. Cytotoxicity assessment using flow cytometry  
The levels of cytotoxicity of C1NCMPs were measured via flow cytometry analysis 
after Annexin V/PI staining. Of the three cancer cell lines tested, H-1975 cells 
appeared more sensitive to the liposomes formulations as relatively lower drug 
concentrations effectively induced cytotoxicity.  In this cell line, C1NCMPs treatment 
at a concentration of 0.75 μM resulted in 38.9% death, after 24 h of exposure which 
is mainly due to induced apoptosis with slight necrosis (˂ 2%), indicating a good 
efficacy of the developed C1NCMPs (Figure 4- 8). Further, the experiments showed 
no significant difference (P˂0.05) between PSL NPs and C1NCMPs in the cytotoxic 
effect after 24 h of exposure with H-1975 cells. 
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Figure 4- 8: The cytotoxicity effect of PSL NPs and C1NCMP (at lipid: Leu:CH
ratio 1:1:0.5 w/w) at concentration 0.75 µM, on H-1975 cells for 24h, following 
which the proportion of apoptosis and necrosis was analysed with Annexin V/PI-
flow cytometry. (Mean ± S.D., n=3).  
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4.5. Discussion  
The size change of any liposomes before and after spray drying is a critical parameter 
in the assessment of liposomal stability so this was used as an initial screening 
parameter when choosing formulations to take forward to the next step of formulation 
optimization. Initially the optimum concentration of either sucrose or trehalose as 
protectants during the SD process was determined. The results obtained for PSL NPs 
in chapter 2 and 3 were promising so these NPs were selected for formulation into dry 
powders for inhalation.  Since PSL NPs have an average size of 46±8.5 nm, they 
cannot directly be used for inhalation as most of the inhaled dose will be exhaled with 
a minimal amount of the dose deposited in the lung [277]. In addition, there are some 
stability issues with using liposome dispersion alone [246].  Therefore, PSL NPs were 
formulated into NCMPs for administration by dry powder inhalation. 
NCMPs were produced by SD using LEU as a carrier and a dispersibility enhancer. 
The geometric particle size of the resultant NCMPs was in the respirable range (2.60 
- 4.85 µm). SEM pictures show irregular or wrinkled surface (Figure 4- 2) which is 
due to an excessive build-up of vapor pressure through water evaporation during the 
SD process and usually occurs with hydrophobic amino acids, such as LEU [241, 278, 
279]. Kunda et al observed the same irregular surface for NCMP containing LEU 
[269]. It is also worth noting that increasing Leu ratio correlated with increased yield 
value. Therefore, L3NCMP (lipid: LEU ratio of 1:1.5 w/w) was selected for further 
studies as it exhibited the highest yield %. This is inconsistent with the results obtained 
by Tawfeek et al., who found that yield increases with increasing Leu ratio in spray 
drying of PGA-co-PDL, 1.5% Leu had the highest value of 54.7 % ±2.6 [241]. 
The size of the CNCMPs was acceptable for respirable particles (3.61-5.39 µm) 
suitable for pulmonary delivery, with a high production yield (63.8-71.8) obtained for 
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all formulations (Table 4- 2). The CH ratio affected the production yield, with an 
increasing ratio of CH resulting in a decreased yield, which can be attributed to some 
of the liquid droplets attaching to the inside wall of the drying chamber and cyclone 
of the spray dryer. This was reported previously by Learoyd et al., with powders 
spray-dried from 30% v/v aqueous ethanol formulations containing terbutaline sulfate 
as a model drug, chitosan as a drug release modifier and leucine as an aerosolisation 
enhancer[280]. Also, Cevher et al prepared biodegradable chitosan microspheres 
containing vancomycin hydrochloride by spray drying with different CH: drug ratios. 
The production yield was relatively low due to powder adherence to the chamber wall 
and reduced cyclone efficiency in collecting the fine powder particles[281]. The SEM 
photographs (Figure 4- 3) demonstrate that the morphology of the CNCMPs is a 
wrinkled (collapsed) surface, which look like raisins and is classified as type III 
(adopting the classification suggested by Prinn K. et al. [37].  At a high CH ratio 
(C4NCMPs), CH effectively imparted a spherical shape and surface smoothness to 
the microparticles. This is due to the rapid internal evaporation of droplets. Wrinkles 
and dents on the surface of spray dried powders have been previously described by 
Tonon et al., when carbohydrates excipients had been used [282]. They found that due 
to the faster water evaporation from droplets during the drying process and 
subsequently when the water fully evaporates, the surface layer collapses resulting in 
the observed wrinkled structure. Increasing CH ratio increases the viscosity of the fed 
solution resulting in slower evaporation. This is in line with He et al, who found that 
chitosan microspheres prepared by a spray drying using a low viscosity solution of 
chitosan had a depressed surface morphology (slightly wrinkled) but those prepared 
from a high viscosity solution of chitosan had a smooth surface [283]. The advantage 
of wrinkled particle surfaces within the spray dried powder is decreasing aggregation 
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from a reduction in cohesiveness and an increase in dispersibility thereby resulting in 
a better lung deposition [284, 285].  
The drug content of CNCMPs was relatively high and the HPLC peaks of AFT 
appears at the same retention time which indicate that AFT is stable during SD. The 
size change of liposomes before and after spray drying is a critical parameter in the 
assessment of liposomal stability. The sizes of the reconstituted liposomes with 
various CH ratios increased when compared to those of the extruded liposomes before 
spray drying (P<0.05). Chitosan was found to have notable effect on increasing the 
size and zeta potentials of reconstituted liposomes. This can be explained by the fact 
that the conventional spray drying and rehydration process may result in liposome 
disruption or aggregation [286]. The higher the ratio of chitosan in formulations, the 
zeta potential changed to less negative values (Table 4- 3). This can be explained by 
the presence of areas uncoated by CH at low CH ratios, since there are not enough CH 
amino groups to complex with LEU. Manca et al, developed rifampicin microparticles 
for delivery to the lungs by coating negative liposomes (∼−46 mV) with chitosan 
(CH)–xanthan gum (XG) to obtain chitosomes [287]. They found that the zeta 
potential of the prepared chitosomes was dependent on CH–XG ratio. When XG 
concentration increased, zeta potential changed to more negative values due to the 
free amino groups complexed with the XG. These results confirmed the effective 
surface coating of liposomes by the CH–XG complexes [287]. 
The CNCMPs formulations showed a slower cumulative release of AFT. It can be 
emphasized that the cumulative amount of AFT release was influenced by the ratio of 
CH. The release rate of AFT decreased with an increase of the ratio of the CH in the 
formulation. The C1NCMPs released 33% AFT after 4 hr, but 24 h dissolution time 
was necessary for the C1NCMPs powder to release more than 89%. The C4NCMPs 
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powder displayed a slower release profile, with 13.25 and 67% drug release after 4 
and 24hr. In contrast, PSL NPs underwent very rapid dissolution, with 100% AFT 
released after approximately 4 hr (Figure 4- 4). This indicates that CH controls the 
drug release of AFT. A DPI formulation containing hydrophobic (beclomethasone 
dipropionate) and hydrophilic (terbutaline sulfate) drugs, leucine (aerosolization 
enhancer) and CH (as a drug release modifier) showed promising sustained release 
delivery of both drugs from a single formulation [287]. Earlier investigators have 
suggested that when microspheres containing hydrophilic polymers such as chitosan 
are immersed in water, diffusion of the drug through a gel diffusion layer produced 
by polymer swelling, results in a sustained drug release effect. Increasing the amount 
of chitosan in the microsphere increases the thickness of this diffusion layer, resulting 
in greater retention of drug release [288-290]. The in vitro release kinetics were 
studied to determine the AFT release mechanism. Afatinib was released from 
CNCMPs formulations according to Higuchi diffusion model. This is because AFT is 
entrapped inside the phospholipid bilayer of the liposomes and must diffuse through 
the bilayer and the CH layer to be released. Therefore, the addition of CH in the 
formulations could successfully prolong the drug release time. Furthermore, a 
potential change in drug release profiles could be achieved depending on the amount 
of CH in the NCMPs. These data were in agreement with a previous study where, 
terbutaline sulfate CH spray-dried powders for inhalation exhibited a sustained release 
profile[280].  
All the CNCMPs powders tested had Lower angles of repose corresponding to freely 
flowing powders [291], low tapped densities, and aerodynamic diameters ˂5 μm, 
indicating that the powders were suitable for deposition in the lungs. The CNCMPs 
powders, when subjected to aerosol performance using the NGI, had MMAD values 
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that were a little higher than the dae values. Higher MMAD values could be the result 
of the aggregation of particles, friction, or interlocking between the particles, which 
might not disaggregate upon aspiration. These MMAD values are in the optimal size 
range of 3.2–5.9 μm indicating the suitability of the NCMPs for targeting deep lung 
airways as reported by different groups of researchers [292, 293]. The % FPF 
characterizes the efficiency of drug deposition in the lower respiratory tract. 
Comparing all formulations, C1NCMPs (at lipid: LEU: CH ratio of 1:1.5:0.5) had the 
highest % FPF and FPD values, 51.2% and 40.0 µg of AFT, respectively, suggesting 
that it was efficient at delivering the most AFT to the lower respiratory tract. This is 
because of the correlation that is seen between FPF and FPD; that is to say, when FPF 
increases, the expected amount of AFT that is delivered to the lower respiratory tract 
also increases, while no clear relationship between MMAD and FPF could be found. 
Also, it is important to note that the MMAD and FPF will also depend on the inhaler 
device. The use of microparticulate Leu as a carrier, in this case, improved the 
aerosolization dispersibility of the PSL NPs powder; but the % FPF was low. It might 
be a result from the agglomeration of microparticulate Leu coated with CH. 
Leucine has previously been shown to enhance a spray dried formulation's 
aerosolization [294]. Learoyd and coworkers reported that the decrease in FPF across 
a series with increased CH molecular weight could be due to the decreased effect of 
LEU surface modification [280]. Two groups of liposomes were prepared, using soy 
phosphatidylcholine and hydrogenated soy phosphatidylcholine, to encapsulate 
rifampicin [287]. The obtained vesicles were then coated with different CH–XG 
weight ratios. The nebulization and rheological properties of powders were affected 
by the CH–XG weight ratio in the formulation. It was concluded that the CS–XG 
weight ratio of 1:0.5 (w/w) coating was able to greatly improve drug deposition (FPF 
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= 37.8%) in comparison with the corresponding uncoated liposomes (FPF = 13%). It 
was suggested that the coating of liposomes with a polyelectrolyte complex at an 
appropriate ratio improved liposome resistance to aerosolization, which suggests that 
CH has an impact on drug dispersion from DPI formulations[287]. 
Liposomal formulation being a carrier for different drug, there are chances that 
formulation may get destabilized over time on exposure to humidity and temperature. 
Liposome systems have been reported to show various physicochemical changes on 
storage, such as liposomal aggregation, fusion, loss of drug, etc. which will affect the 
in vivo performance of the formulation [295] Additionally, phospholipids may 
undergo hydrolysis reaction forming fatty acids and lysophospholipids [296]. 
However, under dried state, there is least possibility for such degradation, but, there 
are still chances of hydrolysis due to residual water content remaining in dried 
powders and also under humid conditions and temperature. Another aspect of stability 
of liposomes is oxidation of lipids. These changes may lead to structural integrity 
problems in liposomes and this might cause release of entrapped drug [297]. Thus, 
these effects induce time dependent changes in desired properties of formulation 
during storage, therefore accelerated and stress stability studies at 40 °C ± 2 °C, 75% 
± 5% RH are potential tools to get an idea of any such possibility. The stability of 
CNCMPs powders showed that there were physical changes during the study period 
and drastic changes in the drug content for all powders. This might be due to the heat 
sensitivity of AFT when exposed to high temperatures for longer times. The stress 
studies showed that the finished product of AFT is sensitive to excessive heat and 
humidity and is sensitive to light exposure therefore needs to be kept in special 
packaging material[298]. Also, both moisture level and thermal processing are 
recognized as crucial parameters affecting the stability of CH-based formulations 
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[299]. ]. Long-term storage at high relative humidity might not only accelerate the 
hydrolytic damage of CH, but also change the polymer’s physicochemical and 
biological properties. Viljoen et al. showed that after six-month storage of CH tablets 
at 70% relative humidity, markedly lower mechanical properties were observed 
compared to those kept at 60% relative humidity [299]. Similar results were observed 
for CH /amylose corn starch composite films that became mechanically weaker after 
three-month storage at the same storage conditions [300]. Furthermore, the studies 
conducted by Lim et al., revealed that both dry heat (160 °C for 2 h) and autoclave 
sterilization (under 100 kPa, at 105–125 °C for 30 min) produced darkening of CH 
dried powder to a yellow color [301]. 
Since C1NCMPs had a higher drug content, yield % and good FPF value indicating 
reasonable probability of deep lung deposition, it was used for cell viability studies 
on H-1975 cell line. The outcome revealed a good cytotoxicity of C1NCMPs as 
compared to drug solution. The cytotoxicity of C1NCMPs was slightly lower than 
that of PSL NPs but the difference was not significant.  This may be attributed to the 
retarded release of AFT from the CNCMPs with CH. Singh et al., studied the lung 
delivery of CH coated cisplatin and higher cytotoxic effects on A549 human lung 
cancer cells and a higher IC50 value were recorded compared with the free drug[302].  
4.6. Conclusion 
The selected PSL NPs formulations were incorporated into NCMPs using LEU to 
enhance powder dispersion. The highest yield % of NCMPs powder (60.2 %) was 
obtained using lipid to LEU 1:1.5 w/w.  This NCMPs at lipd: LEU ratio 1:1.5 was 
coated with different ratios of CH. The morphology of coated NCMPs showed a 
corrugated surface but at high CH ratios, more homogenous and smooth particles with 
some small indentations were obtained. Also, the results showed reproducible size 
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and good AFT content. The in vitro release studies showed a delayed drug release 
compared to PSL NPs. Stability studies showed physical changes and substantial 
changes in the drug content for all coated NCMPs powders during the study period. 
Furthermore, a direct relationship between CH ratio and FPF was observed, 
C1NCMPs (lipid: LEU:CH ratio of 1:1.5:0.5) exhibited the highest FPF (51.2%) and 
FPD (40.0 µg of AFT) indicates deep lung deposition. The cytotoxic study revealed 
that C1NCMPs, at a concentration of 0.75 μM showed a good cytotoxicity effect on 
H-1975 cells, these in vitro results suggest that C1NCMPs could provide a novel 
method of delivering targeted nano-therapy to the lungs in a safe and effective manner. 
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5.1. Overview 
Lung cancer has the highest mortality rate amongst all cancers [303]. The complicated 
genetic and phenotypic levels in cancer cells cause clinical diversity and therapeutic 
resistance in cancer cells. Generally, chemotherapy is the most commonly used 
treatment, but has numerous limitations and side effects [13]. To overcome the 
restrictions of conventional chemotherapy, a number of nanocarrier delivery systems 
have been developed to improve  drug delivery to cancer cells [304]. Currently, 
several nanocarriers such as liposomes, are now on the market, or under research for 
cancer treatment [122]. Liposomes have many advantages for pulmonary delivery, 
over other vehicles as they are prepared from phospholipids endogenous to the lung 
as surfactants [54]. Liposomes can be spray-dried to be formulated as liposomal dry 
powders for inhalation which is a useful technology for pulmonary delivery. The aim 
of this project was to formulate and characterize nanocomposite microparticles of 
AFT-loaded liposomes NPs as a treatment for NSCLC by dry powder pulmonary 
delivery. 
5.2. Optimization of Liposome Nanoparticles  
Precise modification of various formulation and processing parameters is important 
to obtain NPs of a desired size and drug content. In this study, the film hydration 
method was successfully used to actively entrap AFT into liposomes  of small vesicle 
size (<100 nm) with relatively high efficiencies [36]. The PDI values of the obtained 
liposomes were less than 0.27 indicating a narrow size distribution. Afatinib is used 
as a potent antitumor drug against NSCLC tumors. However, AFT alone has low 
specificity and indiscrimination of tumor and healthy tissues [209]. Therefore, AFT 
loaded-liposomes were developed as a new cancer cell therapy with decreased dose-
limiting toxicity. 
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Two different strategies for tumor targeting were selected using cationic and pH-
sensitive phospholipids to produce CL and PSL. The main difference between these 
two liposomes is the composition of phospholipid used. In general, three lipid 
components: DSPC, DOPC, and DOPE were used. The rational for the selection of 
DSPC was its stability against chemical degradation due to being a saturated lipid, 
which reduces drug leakage from liposomes on storage and in vivo transit. To increase 
the fluidity of liposomal membrane, DOPC was selected due to its high fluidity at 
room temperature (transition temperature (Tm) = −20°C). While, the Tm of DSPC is 
+55 °C, which remains in the gel phase [192]. Moreover, DOPE was combined to 
provide fusogenic characters to the liposomes, due to the formation of an inverted 
hexagonal phase upon destabilization of membranes at a mildly acidic pH [84]. Theses 
lipids possess various chain lengths and degrees of saturation, which can fine-tune the 
membrane dynamics and phase properties [193]. The main composition of CL is 
DOTAP, which is a cationic phospholipid and PSL contains the pH-sensitive 
phospholipid, CHEMS. As expected, the zeta potential depends on the lipids used and 
the higher zeta potential of the liposomes obtained produced the stable liposomes.  
In general, a successful drug delivery system should achieve efficient drug 
encapsulation resulting in significant anticancer activity with reduced toxicity [305, 
306]. In order to obtain liposomes with the highest EE%, the optimal ratio of drug to 
phospholipid was determined. It was found that the highest EE% of AFT was 43.20%, 
50.20%, and 52.01% for NL, PSL, CL, respectively at the 1:0.5 ratio of lipid to AFT. 
These results suggest that AFT loading into the liposomes increases only up to a 
certain level with increasing lipid to the drug ratio in the formulation. At higher lipid 
to drug ratios, free drug in the formulation increases which is not a desired feature. A 
similar observation was reported by Mahmud et al. and Myer et al, who found that EE 
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increases only up to a certain level with increasing lipid to drug ratio in the 
formulation [307, 308]. Also, the liposomes incorporated up to 88% paclitaxel when 
the drug to phospholipid molar ratio was 3%. However, a higher drug-to-lipid molar 
ratio would lead to the occurrence of needle-like crystals precipitating during 
preparation [309].  
In vitro drug release data revealed that PSL and NL exhibited sustained release 
profiles due to the presence of DSPC (Tm), which led to a decrease in leakage of AFT 
in the circulation or extracellular environment. But in case of CL, AFT exhibited a 
higher release rate compared with the other liposomes, at pH 7.4. This is due to the 
complete protonation of DOTAP at pH 7.4 [198]. By contrast, the fast drug release 
profile of AFT was found with PSL in acidic media, which reached 100% after 4 h. 
The PSL undergoes destabilization at pH 5.5 and acquires fusogenic properties, thus 
tending to rupture and quickly release AFT. The fusogenic performance of PSL is due 
to the presence of DOPE in the lipid layer, which forms a hexagonal structure instead 
of a bilayer structure after dispersion in aqueous media. These results were consistent 
with results reported by Chen et al. who found that pH-sensitive liposomes of calcein 
had superior pH sensitivity. The rate of release of calcein was less than 10% at pH 
7.0, but gradually increased with decreasing pH. When the pH was decreased from 
6.0 to 5.5, the rate of calcein release increased noticeably while at pH 4.5, the rate was 
nearly 90% [310]. The Reddy group designed novel PSL to co-deliver Paclitaxel and 
Bcl-2 siRNA into the tumor cells and mice models. They observed the highest release 
of siRNA and Paclitaxel (>90% at 6 h time interval) from liposomes at pH 6.5 and pH 
5.5 respectively while in physiological pH (pH 7.4) the release was only 10% [311]. 
According to the kinetic models, the release of AFT at pH 7.4 displayed release with 
Korsmeyer-Peppas model. This effect is due to early rapid release followed by slow 
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release of the liposomes [312]. In case of the release pattern of AFT at pH 5.5 was 
quite faster with a first order model. This behavior because AFT exists liposomal 
membrane, which leaks out at a faster rate in acidic condition [313]. 
5.3. Antitumor activity and Molecular studies 
The potency of free AFT was compared with other common drugs used to treat lung 
cancer. Cell toxicity was evaluated by WST-1 using H-1975 cells. The WST-1 assay 
showed that AFT was more effective as a cytotoxic agent compared to the other 
compounds (H-1975 cells). Furthermore, the anti-proliferative effect of AFT on H-
1975 cells was investigated at various concentrations for 24 h. The results indicated 
that the inhibition of cell viability by AFT was concentration-dependent.  
In two large phase III studies (LUX-Lung 3, and LUX-Lung 6), AFT significantly 
enhanced progression free survival rates, objective response rates compared with 
platinum-based chemotherapy (pemetrexed/cisplatin in LUX-Lung 3 and 
gemcitabine/cisplatin in LUX-Lung 6) as first-line treatment of NSCLC patients [6, 
24, 32]. Additionally, both studies presented AFT to be the only TKI to improved 
overall survival versus standard platinum doublet chemotherapy in patients 
having EGFR mutations [314].  
Anticancer activity of the AFT-loaded liposomes was also investigated with the WST-
1 assay using H-1975 cells. Unfortunately, WST-1 gave unreliable results, therefore, 
the cell viability of each liposome formulation was measured with flow cytometry 
analysis after Annexin V/PI staining.  The flow cytometry data for the treatment of 
cells with different concentrations of PSL exhibited a comparable level of cell 
intensity to free AFT. It was clear that the uptake of AFT loaded PSL by H-1975 cells 
was higher than free AFT. The results revealed a marked decline in cell viability with 
AFT loaded-PSL up to 60.4% of cell apoptosis at 1 µM after 24 h. The free AFT 
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resulted in apoptosis in only 11.88% of the cells after 24 h. The low cytotoxic effect 
of free AFT could be attributed to the low cellular uptake and poor trans-membrane 
permeability. Of the three cancer cell lines tested, H-1975 cells appeared more 
sensitive to the liposomes. Particularly, the cytotoxicity of PSL is high compared with 
that of CL and NL.  
PSL released AFT in response to the lowered pH in the endosome, and thus facilitated 
diffusion of the released AFT from the endosome to the cytosol. It has been suggested 
that pH-sensitive liposomes are internalized more efficiently than non-pH-sensitive 
formulations [43]. It is notable that the destabilization of PSL at the endosomal 
demonstrated that the efficacy of PSL depends on the pH of the tumor tissues [34]. 
Additionally, the liposomes containing CHEMS released their contents into the 
cytoplasm from 5 to 15 min upon their incubation with the cells [44]. The 
destabilization of PSL induced by acidification of the endosomal lumen represents the 
most important stage in the process of intracellular delivery. Kim et al developed a 
PSL with an efficient and targeted delivery system for gemcitabine, and potentially a 
useful, novel treatment approach for tumors that overexpress EGFR [45].  
Quantitative proteomic analysis was used to evaluate the cellular protein changes 
upon AFT treatment. The proteomic analysis revealed a total of 385 proteins were 
differentially expressed from at least one of the four groups; treated and control H1975 
and H1650 NSCLC cells, which help to differentiate treatment effects between the 
sample groups. Correspondingly, the expression of the 385 protein changes across the 
four sample groups were further assessed for their relations with cancer. Analysis 
using IPA software revealed 15 proteins in one of the networks which found in 
multiple categories of functions related to cancer development including cell-to-cell 
signaling and interaction, cell signaling, cell death, cellular growth and proliferation.  
135 
 
These findings indicate that rather than the use of a single marker, analyses of a panel 
of protein markers have the potential to provide better insights and understanding of 
a particular treatment response on NSCLC cells. 
5.4. Spray drying of the selected afatinib loaded liposome 
nanoparticles 
The PSL NPs were dispersed into a L-leucine solution and spray dried to produce 
NCMPs carriers suitable for pulmonary delivery via DPI. The particle size of the 
LNCMPs were 3.57 ± 3.7µm and LNCMPs with a lipid: LEU ratio of 1:1.5 producing 
the highest yield. Photomicrographs of L3NCMPs showed irregular microparticles. 
Therefore, this ratio was selected for further SD studies using different ratios of CH.  
Photomicrographs of CNCMPs powders showed wrinkled particles but at high 
chitosan ratio, more spherical particles were observed with good yield% (63.8 to 71.8 
%).  There was a gradual decrease in the production yield, upon increasing the 
chitosan ratio due to adherence of powders to the wall of the chamber. A few materials 
used as excipients in the spray drying solution have been proved to generate crinkly 
surfaces to some extent for spray dried microspheres such as amino acids, poly- 
saccharides, specifically leucine, chitosan and albumin [278, 283, 315-320]. Sheu and 
coworkers found that the structure of spray dried microcapsules was affected by the 
type of carbohydrate and by the protein to carbohydrate ratio whereas, the extent of 
surface indentation was inversely related to the proportion of protein in the powder 
[321]. 
Spray drying of CNCMPs with chitosan induced a substantial increase in average 
particle size and zeta potential of the developed microparticles. The size of 
reconstituted liposomes from the powders was 60.4 - 89.4 nm depending on the ratio 
of the chitosan and were larger than those of the pre-dried liposomes. The lower the 
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ratio of the chitosan, the smaller the NPs. The difference in mean particle size was not 
signiﬁcant in the lower ratios but was signiﬁcant for higher ratio of CH (P < 0.05).  
The size of the prepared particles was greatly dependent on chitosan ratio [322]. The 
size modifications of the vesicles due to chitosan coating are in line with the results 
obtained by Zaru et al [323]. It is clear that using chitosan in the spray drying has 
shifted the zeta potential toward more positive values. The zeta potential of 
reconstituted liposomes was dependent on the chitosan ratio, at low chitosan ratio 
(C1NCMPs at lipid: LEU: CH ratio of 1:1.5: 0.5), the zeta potential shifted to positive 
values (-14 mV). When the chitosan ratio was increased (C4NCMPs at lipid: LEU: 
CH ratio of 1:1.5: 2), the zeta potential changed to -8.5. This was due to the 
electrostatic interactions which are implicated in the vesicle coating procedure which 
is provided by the fact that the zeta-potential of the vesicles that initially have negative 
charge is drastically changed as the vesicles become coated with polymer [323]. 
The in vitro release profile of AFT from microparticles showed a similar pattern in all 
formulations, slow and steady and the drug release time was prolonged as the chitosan 
content was increased in the formulations. This is in agreement with results reported 
in previous work of Dubey et al [324]. The spray dried powders had good flow 
properties, aerodynamic diameter and drug content. The MMAD values were within 
the optimal size range of 3.2–5.9 μm indicated the suitability of the microparticles for 
targeting deep lung airways as reported by meenach et al [159, 325]. The in vitro 
release profile of AFT from microparticles showed, similar pattern in all formulations, 
slow and steady and the drug release time was prolongated as chitosan content is 
increased in the formulations.  The release mechanism from CNCMPs formulations 
was according to Higuchi diffusion model. Significant decrease in AFT content and 
discoloration in all CNCMPs after storage at 40°C/75% relative humidity for 3 
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months. Yang et al., showed that high temperature produced changes in chitosan dried 
powder to [326]. Furthermore, the studies conducted by Lim et al., revealed that both 
dry heat (160 °C for 2 h) and autoclave sterilization (under 100 kPa, at 105–125 °C 
for 30 min) produced darkening of CH  dried powder to a yellow color [301]. 
As C1NCMPs has a higher drug content, a sustained release profile and FPF value 
with acceptable powder properties, indicative of deep lung deposition. Therefore, the 
cell viability studies were performed on H-1975 cell line. C1 NCMPs appear to have 
a good toxicity profile in comparison with AFT solution. 
5.5. Conclusions 
In this work, a novel PSL NPs for targeted therapy of NSCLC were developed. For 
comparison purpose, NL, CL and PSL NPs were successfully designed. The obtained 
liposomes were small spherical particles of less than 100 nm with a low PDI (<0.27) 
and an acceptable zeta potential. The highest EE% values of the liposomes were 
achieved according the following order: CL>PSL>NL. The selected liposomes were 
stable at 4 and 25°C for 1 month. The PSL, CL and NL showed slow release profiles 
in pH 7.4. However, in acidic pH values, PSL exhibited fast release, which improved 
its tumor targetability. The selected liposomes revealed efficiency on NSCL cells. 
Moreover, PSL NPs inhibited the cell growth of lung cancer cells more efficiently 
than free AFT, CL and NL based on using Annexin V assay. Therefore, the selected 
PSL NPs were incorporated into NCMPs using LEU to enhance powder dispersion. 
The resulted LNCMPs was in the respirable range and the highest yield % obtained in 
lipid: LEU 1:1.5 w/w (60.2 % ±2.8).  This LNCMPs at lipid: LEU ratio 1:1.5 was 
coated with different ratios of CH. The morphology of CNCMPs showed a corrugated 
surface and more smooth particles were obtained at high CH ratios. Also, the results 
showed reproducible size. The in vitro release profiles showed a delayed AFT release 
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compared to PSL NPs. Stability studies showed physical changes and substantial 
changes in the drug content for all CNCMPs powders during the study period. 
Furthermore, C1NCMPs (lipid: LEU:CH ratio of 1:1.5:0.5) exhibited the highest FPF 
(51.2%) and the lowest FPD (28.4 µg of AFT) indicates deep lung deposition. The 
cytotoxic study revealed that C1NCMPs, at a concentration of 0.75 μM showed a 
relatively similar good cytotoxicity effect on H-1975 cells as PSL NPs, these in 
vitro results suggest that C1NCMPs is a promising a targeted drug delivery for 
NSCLC therapy in a safe and effective manner. 
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6.1. Future work 
Moving forward from the achievements of this project, some additional studies 
could be performed to further develop this DDS. 
6.1.1. Optimization of the current formulation 
There is a need for additional investigation and optimization studies to reach the goal 
of a formulation suitable for further in vivo studies. It would thus be of great interest 
to continue developing the current selected formulations with high encapsulation 
efficiency using new elements, such as polymers, in the formulations to achieve an 
improved incorporation of afatinib. Liposome components are not exclusively lipids 
as a new generation liposome, called the polymersomes, can also be prepared from 
polymers. With better stability and versatility than liposomes, polymersomes are 
found many applications in nanomedicine. Hydrophobic, hydrophilic, or amphiphilic 
compounds can be encapsulated in polymersoms, which makes them very attractive 
vesicles for many applications in drug delivery. Thus, highly lipophilic anticancer 
drugs [327, 328]. Studies done by Wang et al has reported that the cationic 
PLGA/folate coated PEGlated polymeric liposome core shell nanoparticles were 
successfully developed for co-delivery of anticancer drug and gene. The nanoparticles 
have core shell structure with nano size, sustained drug release profile and good 
efficacy. which indicated that the drugs and genes carried by the nanoparticles were 
co-delivered into the tumor cells [329]. Rifampicin, first line anti-Tuberculosis drug 
was successfully encapsulated within nanopolymersomes. The polymeric vesicles 
represent a potential platform for inhalable rifampicin therapy. Furthermore, 
rifampicin -loaded nano-sized polymersomes promoted drug accumulation in 
macrophages versus a drug solution representing promising results for a potential TB 
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inhaled therapy [330]. These properties make them more applicable than liposomes 
and other vesicle structures. 
6.1.2. Validation of proteomics data  
Validation of the data obtained by quantitative proteomics, using biological &/or 
biochemical techniques prior to testing in an animal model for future translation into 
humans, is recommended to guarantee significance and reliability of novel 
information. Those techniques do not only validate the quantitative proteomics 
findings but they may also enable information on a protein of interest, as its specific 
activity or cellular location to be obtained. Western blotting, a commonly used 
biochemical method to detect changes in protein abundance, is sensitive, specific, and 
convenient. In order to obtain quantitative data from western blots, a rigorous 
methodology must be used. Briefly, the validation of antibodies is critical both to 
assure that the Ab/antigen interaction is specific and correct and to determine the 
dilution factor of samples that is required for protein loading in the quantitative linear 
dynamic range for each antibody. Furthermore, the appropriate selection of 
normalization method (based on reference signals obtained either by housekeeping 
proteins (HKPs) after immunochemical staining or total protein (TP) intensity on 
blotting membranes after total protein staining) must be considered to assure that the 
reported fold changes of the target protein are not an artifact of reference signal. Thus, 
data normalization is crucial to identify and correct experimental errors where 
reference instability becomes increasingly important with the measurement of smaller 
differences in target protein expression between samples [215, 331].  
Further refinement in animal models for pulmonary drug products is also anticipated 
but also urgently required. To appropriately test inhalation drug products, improved 
animal models are needed since the use of animal models is a prerequisite to 
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substantiate the marketing authorization dossier. These models should be able to 
discriminate between different drug products in terms of aerosol behavior and 
subsequent pharmacokinetics and –dynamics. In addition, the deposition 
characteristics would need to be analyzed. Improvements in methods to determine the 
deposition characteristics in laboratory animals are possible, for example by in vivo 
bioluminescence or fluorescence. 
6.1.3. Stability studies 
Stability studies of any formulation on storage are essential as it reflects whether the 
required properties of the drug and its liposomal formulation are retained on storage.  
investigate the physical stability of liposomes containing AFT under different 
conditions. The chemical stability of AFT and bilayer components was determined as 
well 
These desirable properties include integrity of lipid vesicles and size distribution of 
particles in addition to the stability of the encapsulated drug. Upon storage, liposomes 
are susceptible to many physical changes i.e. lipid particles may undergo fusion and 
aggregation leading to increase in particle size of liposomes. Also, loss of structural 
integrity of liposomes and subsequent leakage of encapsulated drug may take place 
[295]. Liposomal formulations are not stable in an aqueous media. Hence, to increase 
their stability the liposomal formulations are spray dried. However, during spray 
drying the drug and liposomal formulation may undergo aforementioned physical 
changes. The physical testing of such a product should be performed to check whether 
any changes have taken place in the liposomal product in terms of its particle size and 
entrapment efficiency. Thus, following storage, the liposomal formulation, on 
rehydration, should retain the same characteristics it possessed before spray drying. 
For liposomal products, attention has focused on two processes affecting the quality 
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and therefore acceptability of liposomes. First leakage of entrapped molecules from 
the vesicles may occur into the extra liposomal compartment. Secondly, there is a 
possibility of liposomal aggregation and/or fusion, which leads to formation of larger 
particles. Hydrolysis of phospholipids is one of the parameters likely to cause the 
formation of fatty acids and lysophopholipids. Although under dehydrated storage this 
is limited. Another aspect to be considered is liposome oxidation [297].   
As per the ICH stability study guideline, accelerated stability studies should be 
performed on a drug and drug product at accelerated stability testing (25 ± 2 °C/60% 
RH ± 5% RH and at refrigerated conditions (2 - 8 °C) up to 3 months [276]. The 
samples at different temperatures should be withdrawn periodically and analyzed for 
chemical and physical stability as in section (4.3.8.). The stability of the drug within 
the liposomal carrier will be compared to the stability of the drug alone to determine 
if the use of these carriers affords additional stability to the drug. 
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